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 Terpenoid biosynthesis plays essential structural and functional roles in almost all life 
forms. Prenyl transferases, enzymes involved in the isoprenoid metabolism related to prenyl 
chains, transfer allylic prenyl groups to acceptor molecules. Head-to-tail condensations, usually 
of allylic diphosphates (isoprene units), are catalyzed by head-to-tail prenyl transferases 
(commonly referred to prenyl diphosphate synthase), and produce regular terpenes which are by 
far the most common isoprenoid compounds. Head-to-middle prenyl transferases have been 
reported recently and they catalyze the formation of branched products which belong to irregular 
terpenes.  
 Based on the stereochemical outcome of the linear products, head-to-tail prenyl 
transferases can be categorized to two major classes, trans- and cis- prenyl tranferases. Trans-
prenyl transferases are critical players in bacterial respiratory systems while cis-prenyl 
transferases are involved in the biosynthesis of peptidoglycan, essential in bacterial cell wall 
synthesis. Thus, both classes of head-to-tail prenyl transferases are druggable targets in antibiotic 
development. In Chapter 2, I discuss the new series of lipophilic bisphosphonates that inhibit the 
growth of various bacteria and target multiple prenyl transferases. To determine and verify the 
enzyme targets of antibiotic leads, enzyme inhibition assays and bacterial rescue assays were 
performed. In Chapter 3, I discuss the antimicrobial agents phenylthiazoles which target bacterial 
UPPS, YubB (undecaprenyl diphosphate phosphatase (UPPP)) deducted from transposon 
mutagenesis. Putative inner membrane family proteins YubA and YubD are annotated as 
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transporters and may also be targets because the compounds collapsed the proton motive force in 
membrane vesicles.  
 Cis-prenyl transferase UPPS serves as a lipid carrier in cell wall peptidoglycan synthesis 
and catalyzes consecutive condensations of isopentenyl pyrophosphate (IPP) and farnesyl 
pyrophosphate (FPP) to produce C55-PP. The UPPS product has the specific chain length 
essential for the biological function and an intriguing question is how UPPS regulates the 
product chain length. Chapter 4 is focused on chain length regulation mechanism of UPPS and 
its interaction with bacterial membrane.  
 Head-to-middle prenyl transferases catalyze the formation of branched terpenoid 
products, which are reported more recently. It was found that they are highly structurally similar 
to the cis class of head-to-tail prenyl transferases. In Chapter 5, I discuss the first X-ray crystal 
structure of head-to-middle monoterpene synthase, lavandulyl pyrophosphate synthase (LPPS). 
Irregular prenyl transferase LPPS catalyzes two DMAPP molecules and form LPP, a precursor of 
the fragrances (R)-lavandulol and (R)-lavandulyl acetate. The active sites of LPPS were 
examined and compared with cis- head-to-tail prenyl transferase UPPS, and site-directed 
mutagenesis study was conducted. We proposed the first structure-based mechanism of action of 
this unusual prenyl synthase.  
 In Chapter 6, a homolog of LPP, isosesquilavanduly diphosphate (ILPP), and its specific 
enzyme ILPPS were studied, and they are involved in the biosynthesis of the merochlorin class 
of antibiotics found in Streptomyces sp. strain CNH-189. We determined the crystal structure of 
ILPPS, substrate binding, substrate specificity, product length regulation, structure-based 
mechanism and the results were surprising and gave an unexpected perspective into catalysis by 
prenyl transferases. Based on ligand-bound crystal structure, the large, hydrophobic side chain of 
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one substrate does not occupy a central hydrophobic channel. Instead, it occupies a surface 
pocket approximately 90° to the chain axis (hydrophobic tunnel) in other enzymes with cis-
prenyl transferase fold. Interestingly, the proton abstraction is achieved with a diphosphate-Asn-
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CHAPTER 1: INTRODUCTION 
 
1.1 Terpenoids 
The terpenoids are one of the largest and most diverse class of natural compounds 
derived from terpenes which are hydrocarbons.[1] Terpenoids are present in almost all life forms 
and have essential biological functions, such as steroid hormones[2], carotenoids in 
photosynthesis[3], quinones in electron transfer[4], and bacterial cell wall synthesis[5].  
Terpenoids, sometimes called isoprenoids, are composed of various numbers of isoprene 
units (C5).[6] [7] Many, if not most, of the terpenoids originate from the C5 substrates 
dimethylallyl pyrophosphate (DMAPP, Scheme 1.1A) and isopentenyl pyrophosphate (IPP, 
Scheme 1.1A), often followed by condensations of one or more IPP molecules in a head-to-tail 
manner and the formation of linear (C10) geranyl pyrophosphate (GPP), (C15) farnesyl 
pyrophosphate (FPP), Scheme 1.1A.  
1.2 Biosynthesis of Linear Polyprenyl Diphosphates 
Linear polyprenyl diphosphates are the precursors of many terpenoids in nature.[1] The 
biosynthesis of linear polyprenyl diphosphate is catalyzed by prenyl diphosphate synthases, 
commonly referred to prenyltransferases.[8] Prenyltransferases or prenyl transferases are a class 
of enzymes that transfer prenyl groups to acceptor molecules[9], which are prenyl diphosphates in 
this dissertation. These linear prenyl pyrophosphates are the common precursors of carbon 
skeletons of terpenoids.[10] Thus, these terpenoids are called regular terpenoids and their 
synthases are called regular terpene synthases or prenyl transferases.[11]  
Head-to-tail prenyl transferases (PTs) catalyze the condensation of linear polyprenyl 
diphosphates and PT can be categorized as trans- and cis- prenyl transferases, depending on the 
geometry or stereochemical outcome of products[1] (Scheme 1.1B). Similarly, both reactions 
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involve pyrophosphate release and attack of carbon cation (Scheme 1.1B).[12] In the trans-prenyl 
transferases, pro-R proton is abstracted, together with the simultaneous formation of a new trans 
double bond.[13] In the cis-prenyl transferases, pro-S proton is abstracted, facilitated by the 
nearby nucleophile.[12] [14] 
1.3 Trans- and Cis- Head-to-Tail Prenyl Transferases in Bacteria 
Two families of trans- and cis-prenyl transferases (head-to-tail) in bacteria have 
completely different biological functions. Among trans-prenyl transferases, trans-farnesyl 
pyrophosphate synthase (FPPS, Scheme 1.1A) plays important roles in the biosynthesis of 
steroids, cholesterol, heme and quinones.[4] On the other hand, cis-prenyl transferases play 
important roles in the bacterial cell wall biosynthesis. For example, cis-Undecaprenyl 
pyrophosphate synthase (cis-UPPS, Scheme 1.1A), catalyzing the formation of cis-C55-PP, is the 
indispensable lipid carrier for peptidoglycan synthesis in many bacteria, followed by the cell wall 
formation. [5] [10]  
These head-to-tail prenyl transferases catalyze the condensations of polyprenyl 
diphosphates with specific chain lengths, which are essential to the bacterial biological 
functions.[10] Increasing numbers of crystal structures of head-to-tail prenyl transferases reported 
shared enzyme structures, substrate binding sites, elucidated the mechanisms of action (reaction) 
as well as product chain length regulation. 
X-ray crystal structures of octaprenyl pyrophosphate synthase (OPPS) from E. coli (PDB 
ID code 3WJN, 3WJO)[15] are shown in Figure 1.1, as a representative structure of trans- prenyl 
transferases. OPPS catalyzes the condensation of FPP and 5 IPP consecutively and forms all-
trans (C40) OPP (Scheme 1.2), which is the precursor of ubiquinones and menaquinones.[16] The 
structure is a homodimer and composed entirely of helices.[16] Two highly conserved Asp-rich 
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motifs in trans-prenyl transferases, shown in sequence homology[17], were recognized in crystal 
structures[16] and involved in the substrate binding and condensation, via coordination with Mg2+ 
ions, based on site-directed mutagenesis studies.[18]–[21] Two DDXXD motifs, located in the two 
helices, face each other and form the substrate binding sites for FPP and IPP.[15] [16] The deep 
cleft (hydrophobic channel), where two DDXXD motifs are located, facilitates and controls the 
elongation of product chain lengths.[16] In EcOPPS, site-directed mutagenesis studies indicate the 
residues Ser-77, Ala-76, Phe-132 in the hydrophobic channel are critical in determining the 
product chain lengths. [16] In Staphylococcus aureus (S. aureus), the corresponding long-chain 
prenyl transferase of OPPS, is C35 Heptaprenyl pyrophosphate synthase (HepPPS, Scheme 1.2) 
which is found to be a heterodimer and composed of a large “catalytic” domain and a small 
regulatory domain that are both essential to the catalysis.[22] 
The amino acid sequences and 3-D structures of cis-prenyl transferases are completely 
distinct from those of trans-prenyl transferases.[14] One important cis-prenyl transferase is 
undecaprenyl pyrophosphate synthase (UPPS) which synthesizes cis-UPP (C55), Scheme 1.1, 
dephosphorylated to cis-undecaprenyl (mono) phosphate, which then serves as a lipid carrier for 
the peptidoglycan biosynthesis.[5] [10] UPPS is absent in human and an essential enzyme in many 
bacteria[23], which makes it an attractive enzyme target in the endeavor of antibiotic discovery[24]. 
Figure 1.2 shows the homodimeric structure of E. coli UPPS (PDB ID 1X08, 1X09)[25] 
where the conservative hydrophobic channel, composed of two 𝛼-helices and four 𝛽 -sheets, 
binds the substrates and elongates the linear prenyl chains. Both ligands have electrostatic 
interaction with Mg2+ which is coordinated by a conserved aspartate (Asp26 in EcUPPS).[25] 
Other critical conserved Asp and Glu (Asp150 and Glu213 in EcUPPS) was examined and found 
to be important in substrate binding and catalysis.[26] Two different protein conformations were 
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seen in the two subunits (chains) of EcUPPS, and the main difference is the spatial position of 
𝛼3 helix.[5] The flexible loop, connected to the 𝛼3 helix, was proposed to work as a hinge 
between two conformers.[5] A Trp residue (Trp91 in EcUPPS) in the flexible loop was found to 
be important in FPP (substrate) binding and condensation, based on the fluorescence 
experiments.[27] It was suggested that the closed conformation facilitates the binding of substrates 
and intermediates, followed by the open form for the product release.[12] 
The hydrophobic tunnel, including the residues on the bottom of the tunnel, regulates the 
product chain lengths in EcUPPS.[12] In the in vitro reaction, the presence of 0.1% Triton 
significantly increased the kcat value, and Triton was found to facilitate the product release.[28] 
Chapter 4 in this dissertation is mainly focused on the UPPS product length regulation and its 
interaction with membrane lipids. 
1.4 Multi-Target Antibiotic Discovery Acting in Terpenoid Biosynthesis 
Alarmingly, antimicrobial resistance has been a public health crisis in recent years.[29] 
Two attractive drug discovery strategies, combination and multi-targeting, have been adopted 
and developed to combat the antibiotic resistance.[30] 
The root cause of many antibiotic resistance cases is the mutation(s) of protein targets, 
followed by the low or no efficacy of the antibiotic (protein inhibitor).[30] In general, if the drug 
has two targets (multiple mechanisms of action), the likelihood that mutations developing in both 
targets will be a small number.[30] And the most successful monotherapy antibiotics have more 
than one targets.[31] [32] 
For an individual drug candidate with single protein target, there are at least 10 
requirements or factors, including but not limited to the efficacy, ADME (adsorption, 
distribution, metabolism, and excretion), toxicity, large-scale manufacturing cost analysis, and 
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intellectual property.[30] The combination therapy with two new drugs would involve at least 20 
requirements to be fulfilled, which is a daunting challenge and would involve a significant cost 
increase in various aspects.[30] On the other hand, the drug discovery using multi-target strategy 
could potentially significantly ease the process and lower the costs, which would be desirable.[30] 
There are good examples of drug discovery work focused on dual-targeting and multi-
targeting.[33]–[37] Overall, multi-targeting approach can be effective in antibacterial discovery and 
development.  
The approach to target metabolic pathways was quoted in the FDA guidelines for novel 
anti-infective development.[38] Targeting dual or multiple enzymes in the same or related 
metabolic pathways would be promising due to the coupled reactions and very likely synergistic 
interactions.[30] Among the metabolic pathways, enzymes in the terpenoid biosynthesis, 
especially those involved in the quinone and bacterial cell wall synthesis, are of great interest for 
novel antimicrobial inhibitor discovery. Chapter 2 and 3 in this dissertation report the discovery 
of antimicrobial agents with multiple mechanisms of actions in these terpenoid biosynthesis 
pathways, and the enzyme targets include trans- and cis- head-to-tail prenyl transferases.  
1.5 Head-to-Middle Prenyl Transferases 
A unique cis-type prenyl transferase with significant homology to cis-PT, was reported 
and termed lavandulyl pyrophosphate synthase (LPPS).[39] Irregular prenyl transferase LPPS, 
from Lavandula x intermedia, specifically catalyzes the head-to-middle condensation of two 
dimethylallyl pyrophosphate (DMAPP) molecules and forms a branched (C10) lavandulyl 
pyrophosphate (LPP), Scheme 1.3.[39] LPP product is the important, branch point, precursor of 
lavandulol and lavandulyl acetate.[40] In Chapter 5, I report the X-ray structure of LPPS and 
compare with head-to-tail cis-prenyltransferases comprehensively. We utilized functional assays, 
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various bioinformatics and structure-based tools to firstly elucidate the mechanism of action of 
the head-to-middle prenyl transferases or synthases. 
Another recent work reported an unusual homolog of LPP, (C15) isosesquilavandulyl 
pyrophosphate (ILPP), found in Streptomyces sp. strain CNH-189 and the reaction is catalyzed 
by isosesquilavandulyl pyrophosphate synthase, ILPPS or Mcl22.[41] ILPP is the precursor of a 
merochlorin class of antibiotics, which are cyclic meroterpenoids.[41] Deletion of gene mcl22 
completely abolished the generation of merochlorin derivative in Streptomyces host strain.[42] 
ILPPS or Mcl22 catalyzes the condensation of GPP and IPP and formed the branched product 
(C15) ILPP[41], Scheme 1.3.  
After determination of the apo and ligand-bound structure of ILPPS, we aim to elucidate 
the detailed mechanism of this unique head-to-middle condensation by examining another head-
to-middle terpene synthase (LPPS) and cis-prenyl transferases, shown in Chapter 6. Interesting 
substrate binding pockets were investigated, and site-directed mutagenesis studies revealed the 
specificity mechanism of ILPPS substrates and product. Combined structure and function 
characterization led to the elucidation of the mechanism of action and unexpected findings of 





1.6 Schemes and Figures 
Scheme 1.1 Head-to-tail condensations of linear pyrophosphates discussed in the text. Terpenoid 




Scheme 1.2 Reactions and functions of head-to-tail prenyl transferases, heptaprenyl 
pyrophosphate synthase (HepPPS) and octaprenyl pyrophosphate synthase (OPPS). 
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Figure 1.1 Homodimeric X-ray structures of octaprenyl pyrophosphate synthase (OPPS) from E. 
coli (PDB ID code 3WJN, 3WJO) in complex with FSPP. Two monomers are shown in cartoon 
in yellow and blue, respectively. S-thiolo FPP analog, FSPP, is shown in brown stick. Mg2+ ions 




Figure 1.2 Homodimeric X-ray structures of undecaprenyl pyrophosphate synthase (UPPS) from 
E. coli (PDB 1X08, 1X09). A) Two monomers are shown as green and orange cartoons, 
respectively. S-thiolo FPP analog FSPP is shown in sphere. B) One monomer is shown in 
cartoon while another monomer is shown in surface (back). Two ligands, FSPP and IPP, are 
shown in stick and Mg2+ is shown in sphere. 




Scheme 1.3 Reactions of head-to-middle prenyl transferases (lavandulyl pyrophosphate synthase 
and isosesquilavandulyl pyrophosphate synthase, LPPS and ILPPS). 















GPP = Geranyl pyrophosphate
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Lipophilic Bisphosphonates Target Bacterial Cell Wall and Quinone Biosynthesis.  
2.2 Introduction 
 
There is a need for new antibiotics because of the rise in drug resistance and in our group, 
we have been investigating enzymes involved in isoprenoid biosynthesis as potential anti-
infective drug targets.[1] These enzymes include farnesyl diphosphate synthase (FPPS) and 
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undecaprenyl diphosphate synthase (UPPS), both of which are involved in bacterial cell wall 
biosynthesis, and we discovered several inhibitors[2, 3], one of which was active in vivo in a 
mouse model of Staphylococcus aureus infection.[2] We also recently discovered[4] several 
inhibitors of S. aureus heptaprenyl diphosphate synthase (SaHepPPS), essential for the formation 
of menaquinone, required for electron transport (ET) and hence, ATP synthesis, in many 
bacteria⎯and as with UPPS, this enzyme is not produced by humans. Here, we sought to find 
new inhibitors that might target E. coli octaprenyl diphosphate synthase (EcOPPS) or 
Staphylococcus aureus heptaprenyl diphosphate synthase (SaHepPPs) and hence, quinone 
biosynthesis. A simplified version of the enzymes involved in quinone as well as cell wall 
biosynthesis in many bacteria is shown in Figure 2.1A, together with the sites of action of several 
antibiotics, and in Figure 2.1B we show the chemical structures of selected substrates/products in 
S. aureus. 
Isoprenoid biosynthesis begins with the formation of two C5-isoprenoid diphosphates, 
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) which are produced by 
either the mevalonate (MEV) pathway, as in S. aureus, or by the so-called non-mevalonate or 
deoxyxylulose-5-phosphate (DXP) pathway, the latter being far more common than the MEV 
pathway. These two isoprenoids are then condensed to form (C10) geranyl diphosphate and then, 
via addition of a second IPP, to farnesyl diphosphate (FPP), both reactions being catalyzed by 
the enzyme farnesyl diphosphate synthase (FPPS). FPP is then elongated by further reactions 
with IPP to produce long chain (typically all-trans C30, C35, C40) diphosphates that then react 
with DHNA 1,4-dihydroxy-2-naphthoic acid (DHNA) to form quinone precursors, Figure 2.1B. 
In some bacteria (e.g. E. coli), both menaquinonees and ubiquinones are formed. FPP is also 
converted to very long-chain cis-isoprenoids such as undecaprenyl diphosphate (UPP), in 
reactions catalyzed by undecaprenyl diphosphate synthase (UPPS), with UPP being converted to 
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undecaprenyl (mono)phosphate (UP) by undecaprenyl diphosphate phosphatase (UPPP), the 
target for the antibiotic bacitracin, essential for cell wall peptidoglycan biosynthesis.  
OPPS is an essential gene in E. coli[5] and catalyzes the formation of the C40 isoprenoid 
octaprenyl diphosphate (OPP) from farnesyl diphosphate (FPP) and five molecules of 
isopentenyl diphosphate (IPP). Its structure is known[6] and is highly -helical, resembling that 
of other trans-prenyltransferases, such as FPPS.[7] Since OPPS is absent in humans, this makes it 
a potential anti-microbial drug target. There are, however, no reports of bacterial OPPS inhibitors. 
In S. aureus, the corresponding long-chain prenyl transferase is the C35 heptaprenyl diphosphate 
synthase, SaHepPPS. This has a somewhat unusual heterodimeric structure[4] consisting of a 
large, "catalytic" domain (SaHepPPS-2) and a small, regulatory domain (SaHepPPS-1), and both 
are essential for activity. Similar heterodimeric structures are found in some other bacteria—such 
as Micrococcus luteus,[8] Bacillus spp. and Enterococcus spp.—and the structures of the catalytic 
sites in OPPS, HepPPS as well as FPPS are quite similar. In this work, we first sought to find 
inhibitors of OPPS and HepPPS, active in cells, then we extended this work to better understand 
inhibitor mechanisms of action, in addition to solving several structures of interest. 
In order to find new, long-chain prenyl synthase inhibitors we first screened a library of 
previously-reported compounds including bisphosphonates, benzoic, salicylic, anthranilic and 
diketoacids, for OPPS inhibition, since these classes of compounds were shown to inhibit 
prenyltransferases[2], and some have anti-bacterial activity. We then screened a subset of 
compounds for bacterial cell growth inhibition (against S. aureus, B. subtilis, B. anthracis Sterne, 
Mycobacterium smegmatis, E. coli, Acinetobacter baumannii, Klebsiella pneumoniae, 
Pseudomonas aeruginosa) as well as the fungus, Candida albicans, and used the results obtained 
to guide the synthesis of 30 new compounds. We investigated the mechanism of action of some 
of the most potent compounds in cells using enzyme inhibition assays, as well as bacterial cell 
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growth inhibition “rescues” by putative enzyme end-products. We also determined activity 
against Clostridioides difficile, a bacterium that does not use quinones (or hemes) in ATP 
biosynthesis, again to help clarify mechanisms of antibacterial action. Finally, we solved several 
X-ray crystal structures, to determine inhibitor binding modes. Overall, the results are of general 
interest since we have discovered several potent multi-target antimicrobial agents inhibiting 
quinone as well as cell wall biosynthesis. 
 
2.3 Material & Methods  
2.3.1 Phosphate Release Activity Assay (Enzyme Inhibition Assay) 
The Reaction kinetics were monitored using a continuous spectrophotometric assay for 
inorganic phosphate release with the substrate 2-amino-6-mercapto-7-methylpurine (MESG), 
and enzyme purine nucleoside phosphorylase (PNP).[9] For the prenyltransferase enzymatic 
assays, inorganic pyrophosphatase (Ppase) was added to the reaction to convert each 
pyrophosphate to two inorganic phosphates. The inorganic phosphate then reacts with MESG in 
a PNP catalyzed reaction. Because the 2-amino-6-mercapto-7-methylpurine product has an 
absorption peak at 360nm and coupled reactions catalyzed by Ppase and PNP are instant, the 
enzymatic kinetics of FPPS, OPP, HepPPS, UPPS and UPPP can be directly monitored at 
360nm. The total volume of each reaction was 200μL, with 100μL reaction mix being added to 
100μL of protein mix. The reactions were continuously monitored on a spectrophotometer at 
room temperature until there was no longer an increase in absorbance at 360nm, indicating the 
completion of the enzymatic reaction. 20mM IPP, FPP, and GPP substrate stock solutions were 
prepared in water. 
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The same procedure above was followed for the compound inhibition assays, except that 
prior to the addition of reaction mix to the protein mix, the protein mix was incubated with serial 
dilutions of the compound for 30 minutes at room temperature. 10mM compound stocks were 
used and they were dissolved in H2O. All assays were performed in at least 3 independent 
repeats, and dose-response curves were analyzed in GraphPad Prism using non-linear regression 
function. 
FPPS Enzymatic Assay 
Expression, purification and storage of HsFPPS were conducted as previous report.[10] 
The enzyme kinetics assays at 25°C were performed in a mixture of 50μM IPP and 50μM GPP, 
0.3 unit of PNP (Sigma-Aldrich, 10 units/mg), 0.6 unit of Ppase (Sigma-Aldrich, 500 units/mg), 
0.1 mg/mL MESG, and 0.15μM HsFPPS in the activity buffer containing 20mM HEPES (pH 
7.5), 150mM NaCl, 500μM MgCl2. 
OPPS Enzymatic Assay 
Expression, purification and storage of EcOPPS were conducted as previous paper.[11] 
The enzymatic assays at 30°C were executed in the reaction mixture of 50μM IPP and 5μM FPP, 
125 nM EcOPPS, 0.3 unit of PNP (Sigma-Aldrich), 0.6 unit of Ppase (Sigma-Aldrich), 0.1 
mg/mL MESG in the activity buffer containing 100mM HEPES-KOH (pH 7.5), 0.1% TX-100, 
50mM KCl, 0.5mM MgCl2. 
HepPPS Enzymatic Assay 
Expression, purification and storage of HepPPS were conducted as previous report.[12] 
The enzymatic assays at 30°C were conducted in the reaction mixture of 40μM IPP, 10μM FPP, 
300nM SaHepPPS, 0.3 unit of PNP (Sigma-Aldrich), 0.6 unit of Ppase (Sigma-Aldrich), 0.1 
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mg/mL MESG in the activity buffer containing 10mM HEPES (pH 7.5), 150mM NaCl, 1mM 
MgCl2. 
UPPS Enzymatic Assay 
Expression, purification and storage of EcUPPS were conducted as previous paper.[3] The 
enzymatic assays at 25°C were conducted in the reaction mixture of 50μM IPP, 6μM FPP, 63nM 
EcUPPS, 0.3 unit of PNP (Sigma-Aldrich), 0.6 unit of Ppase (Sigma-Aldrich), 0.1 mg/mL 
MESG in the activity buffer containing 100mM HEPES (pH 7.5), 50mM KCl, 0.5mM MgCl2, 
0.1% Triton-100 (v/v). 
UPPP Enzymatic Assay 
Expression, purification and storage of EcUPPP were conducted as previous paper.[13] 
The enzymatic assays at 25°C were performed in the mixture of 25μM FPP, 125nM EcUPPP, 0.3 
unit of PNP (Sigma-Aldrich), 0.1 mg/mL MESG in the activity buffer containing 50mM HEPES 
(pH 7.0), 150mM NaCl, 1mM CaCl2, 0.016% DDM (w/v). 
2.3.2 Cell Assays and Chemicals 
Material (Cells and Chemicals) 
Bacteria were obtained from the following sources: B. subtilis from subsp. subtilis 
(Ehrenberg) Cohn ATCC 6051; E. coli (k12); S. aureus (Newman strain); B. anthracis (str. 
stern); A. baumannii (Bouvet and Grimont, ATCC 19606); K. pneumoniae (subsp. pneumoniae 
Schroeter Trevisan ATCC 27736); P. aeruginosa (PA01), HEK293 cells were from HEK293 
ATCC CRL-1573. 
We obtained decaprenyl monophosphate (DP) and undecaprenyl monophosphate (UP) 
from Larodan AB, Sweden (Product # 62-1050-2, and 62-1055-2) Menaquinone-4 (MK-4) was 
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from SIGMA-ALDRICH (product # 47774). DP and UP were dissolved in 1:1 MeOH:DMSO, 
while MK-4 was prepared as a dispersion in ethanol. 
B. subtilis growth inhibition assay 
An overnight starter culture (in LB both) of B. subtilis was diluted 1000-fold (in fresh LB 
media) and grown to an OD600 value of ~0.3 (approx. 3.5 hours at 37 °C). This log-phase 
culture was then diluted 500-fold into fresh LB broth to generate the working solution. 180 μL of 
this working solution was then transferred into every well in a flat-bottom 96-well plate, except 
for the first column. Inhibitors were added at specific starting concentrations (100 μM – 1 mM) 
with a total volume of 360 μL (diluted with working solution) into the first column. The 
inhibitors were then sequentially diluted two-fold across 12 wells. Plates were incubated at 37 °C, 
shaking at 200 rpm for 12 hours. The OD600 values were then measured to determine bacterial 
growth inhibition using Origin software to determine ED50 values.  
B. subtilis DP, UP and/or MK4 rescue assays: An overnight starter culture (in LB both) 
of B. subtilis was diluted 1000-fold (in fresh LB media) and grown to an OD600 value of ~0.3 
(approx. 3.5 hours at 37 °C). The working solution was prepared by 500-fold dilution of this log 
phase-culture into fresh LB broth. Then, 50 μM UP and/or 50 μM MK4 working solutions for 
cell-growth-inhibition “rescue” experiments were prepared using the 500-fold diluted working 
solution; 200 μL of this working solution was then transferred into every well in a flat-bottom 
96-well plate, except for the first column. Inhibitors were added at specific starting 
concentrations (100 μM – 1 mM) with a total volume of 300 μL (diluted with working solution) 
into the first column. The inhibitors were then sequentially diluted threefold across 12 wells. 
Plates were incubated at 37 °C, shaking at 200 rpm for 12 hours. The OD600 values were then 
measured to determine bacterial growth inhibition and hence, any rescue effects.  
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S. aureus growth inhibition assay: An overnight starter culture of S. aureus was diluted 
1000-fold (in fresh Tryptic soy media) and grown to an OD600 value of ~0.3 (approx. 3.5 hours 
at 37 °C). This log-phase culture was diluted 500-fold into fresh Tryptic soy broth to generate the 
working solution. 180 μL of this working solution was then transferred into every well in a flat-
bottom 96-well plate, except for the first column. Inhibitors were added at specific starting 
concentrations (100 μM – 1 mM) with a total volume of 360 μL (diluted with working solution)  
B. anthracis Sterne growth inhibition assay: An overnight starter culture of B. 
anthracis Sterne was diluted 1000-fold (in fresh Mueller-Hinton Broth 2 media) and grown to an 
OD600 value of ~0.3 (approx. 3.5 hours at 37 °C). This log-phase culture was diluted 500-fold 
into fresh MHB broth to generate the working solution. 180 μL of this working solution was then 
transferred into every well in a flat-bottom 96-well plate, except for the first column. Inhibitors 
were added at specific starting concentrations (100 μM – 1 mM) with a total volume of 360 μL 
(diluted with working solution) into the first column. The inhibitors were then sequentially 
diluted twofold across 12 wells. Plates were incubated at 37 °C, shaking at 200 rpm for 12 hours. 
The OD600 value was then measured to determine bacterial growth inhibition.  
B. anthracis Sterne UP, MK4, HMBPP, and FPP rescue assay: An overnight starter 
culture of B. anthracis Sterne was diluted 1000-fold (in fresh Mueller-Hinton Broth 2 media) and 
grown to an OD600 value of ~0.3 (approx. 3.5 hours at 37 °C). The working solution was 
prepared by 500-fold dilution of this log phase-culture into fresh MHB broth. Then, 50 μM 
working solutions of rescue were prepared using the 500-fold diluted working solution; 200 μL 
of this working solution was then transferred into every well in a flat-bottom 96-well plate, 
except for the first column. Inhibitors were added at specific starting concentrations (100 μM – 1 
mM) with a total volume of 300 μL (diluted with working solution) into the first column. The 
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inhibitors were then sequentially diluted threefold across 12 wells. Plates were incubated at 
37 °C, shaking at 200 rpm for 12 hours. The OD600 value was then measured to determine 
bacterial growth inhibition.  
M. smegmatis growth inhibition assay: M. smegmatis (grown for 36-48 hours) was 
diluted 1000-fold in fresh Middlebrook 7H9 (10% define, Sigma: M0553-1VL, 0.5% glycerol, 
0.05% Tween 80) media) to generate a working solution. 180 μL of this working solution was 
then transferred into every well in a flat-bottom 96-well plate except for the second column 
(from the left side of the plate) and peripheral wells (the outermost row that encircles all of the 
inner wells). Inhibitors were added at specific starting concentrations (100 μM – 1 mM) with a 
total volume of 300 μL (diluted with working solution) into the second column. The inhibitors 
were then sequentially diluted threefold across 10 wells; 200 μL of water was added to each 
peripheral well to prevent evaporation. Plates were incubated at 37 °C, shaking at 200 rpm for 48 
hours. The OD600 value was then measured to determine bacterial growth inhibition.  
C. difficile assay. Clostridioides difficile were grown anaerobically on brain heart 
infusion supplemented agar plates (Brain heart infusion medium, BD, supplemented with yeast 
extract, L-cysteine, vitamin K1 and hemin) at 37 ̊C for 48 hours. Then, a bacterial solution 
equivalent to 0.5 McFarland standard was prepared and diluted in brain heart infusion-
supplemented broth to achieve a bacterial concentration of ~5 x 105 CFU/mL and seeded into 
96-well well plates. Inhibitors were added at a concentration of 64 μM in the first row of the 96-
well plates and diluted along the plates to achieve a range of 64-0.5 μM. Plates were then 
incubated anaerobically at 37 ̊C for 48 hours. MICs values reported are the minimum 
concentrations of the inhibitor that could inhibit visual growth.  
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2.3.3 EcOPPS expression, purification, crystallization, data collection, structure 
determination, and refinement. 
EcOPPS was expressed and purified as described previously.[14] Briefly, a pET46Ek/LIC-
EcOPPS plasmid was transformed into E. coli BL21trxB (DE3) for expression. EcOPPS was 
induced with 0.8 mM isopropyl-thiogalactopyranoside (IPTG) at 37 °C for 4 h and the target 
protein purified by using a Ni-NTA column, then a DEAE Sepharose Fast Flow column (GE 
Healthcare Life Sciences). The eluted EcOPPS was then dialyzed twice against 5 L buffer (25 
mM Tris•HCl, pH 7.5, 150 mM NaCl) and concentrated to 3 mg/mL for crystallization screening.  
All crystallization experiments were conducted at 22 °C using the sitting-drop vapor-
diffusion method. In general, 2 μL of EcOPPS-containing solution (25 mM Tris•HCl, 150 mM 
NaCl, pH 7.5; 3 mg/mL) was mixed with 2 μL of reservoir solution in 24-well Cryschem Plates 
(Hampton Research), and then equilibrated against 300 μL of reservoir solution. The optimized 
crystallization condition for EcOPPS was 0.3 M MgCl2, 0.1 M Tris•HCl, pH 8.5, and 24% w/v 
PEG 3350. Within 3 to 4 days, the crystals reached dimensions suitable for X-ray diffraction. 
EcOPPS crystal in complex with BPH-629 were obtained by soaking the apo-crystals with 
cryoprotectant solution (0.3M MgCl2, 0.1M Tris•HCl, pH 8.5, 28 % w/v polyethylene glycol 
3350, and 4 % v/v glycerol) containing 5 mM BPH-629 for 3 h.  
X-ray diffraction data-sets for EcOPPS in complex with BPH-629 collected at beam line 
BL13B1 of the National Synchrotron Radiation Research Center (NSRRC, Hsinchu, Taiwan). 
Crystals were mounted in a cryoloop and soaked with their cryoprotectant solution prior to data 
collection at 100 K. The diffraction images were processed by using HKL2000.[15] Prior to 
structure refinement, 5 % randomly selected reflections were set aside for calculating Rfree[16] as a 
monitor of model quality. The complex structures of EcOPPS•BPH-629 was determined by 
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using the MR method with Phaser[17] from the CCP4i program suite[18] using the refined EcOPPS 
structure (PDB code 3WJK[6]) as a search model. The model and map were further improved by 
refinement using Refmac5[19] and Coot[20]. All figures were prepared by using the PyMOL 
program (http://pymol.sourceforge.net/).  
2.4 Results & Discussions 
2.4.1 Initial Screening Results 
We first investigated the inhibition of E. coli octaprenyl diphosphate synthase (EcOPPS) 
since in previous work we found that this protein was more stable than the corresponding 
enzyme from S. aureus, SaHepPPS, and has a better resolved crystal structure. We screened a 
diverse range of potential inhibitors: bisphosphonates, phosphonates, benzoic/anthranilic acids, 
and amines/diamines/diamidines, classes of compounds that in earlier work[2] we found inhibited 
prenyltransferases such as FPPS[3], geranylgeranyl diphosphate synthase (GGPPS)[21], HepPPS[4], 
UPPS[2], MenA (1,4-dihydroxy-2-naphthoate polyprenyltransferase)[4] and dehydrosqualene 
synthase[1]. About one-third of the compounds had essentially no activity (IC50 >1 mM) against 
EcOPPS, but there were several compounds having low nM activity. All of the most potent hits 
were bisphosphonates, the most active species (BPH-715, Figure 2.2) having an IC50 value of 
~5.6 nM. The lipophilic benzoic/anthranilic/salicylic acids were all much less active, the most 
potent species having an IC50 ~5 µM. 
We then tested BPH-715, together with 5 other compounds (BPH-364, 642, 981, 629, 
1463; Figure 2.2), against S. aureus, B. subtilis, B. anthracis Sterne, M. smegmatis, E. coli, A. 
baumannii, K. pneumoniae, P. aeruginosa as well as C. albicans, Table 3.1. There was little to 
no activity (EC50 > 50 µg/mL) against the gram-negative bacteria or C. albicans, but there was 
activity in the ~3-8 µg/mL range for some compounds against S. aureus, M. smegmatis, B. 
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subtilis or B. anthracis Sterne, Table 2.1. The lack of activity against the gram-negative bacteria 
was unexpected because in previous work[12] we found that lipophilic bisphosphonates such as 
BPH-1625 (Figure 2.2) had quite potent (~2 µg/mL) activity against the same gram-negative 
bacteria tested here, but they had low activity against the gram-positive bacteria S. aureus (30 
µg/mL) and B. subtilis (> 100 µg/mL). However, with BPH-715, we see the opposite trend and 
one possibility is that the presence of an aromatic group “distal” to the bisphosphonate backbone 
(seen also with BPH-210, Figure 2.2)[22] is required for transport into the gram-negative bacteria. 
What is also interesting about the bisphosphonate results presented here is that the 
patterns of OPPS inhibition are similar to those we find with the shorter (C15) prenyl synthase 
FPPS, as opposed to the longer (C20) chain synthase, geranylgeranyl diphosphate synthase 
(GGPPS). For example, BPH-91 (zoledronate, Figure 2.2) is a ~50 nM inhibitor of OPPS as well 
as of human FPPS,[10, 23] but only a very weak (IC50 ~100 µM) inhibitor of human GGPPS.[24] 
For potent FPPS inhibition, we proposed previously[25] [26] [27] that there was a requirement for 
either a cationic or protonatable group close to the bisphosphonate backbone for activity, 
mimicking a reactive intermediate in FPPS catalysis. There was, however, no requirement for 
such a cationic feature for GGPPS inhibition.[24] For example,[28] BPH-715, containing a cationic 
charge center, has an IC50 = 100 nM for FPPS inhibition and an IC50 = 280 nM for GGPPS 
inhibition, while BPH-754 (Figure 2.2), which lacks this feature, has an IC50 = 550 µM for FPPS 
inhibition but an IC50 = 590 nM for GGPPS inhibition.[28] Here, we find that BPH-754 has an 
IC50 = 11 µM against OPPS, while BPH-715 is far more potent with an IC50 = 20 nM (Figure 
2.3A). The trends are similar with larger species such as BPH-364 and BPH-608 (Figure 2.2) in 
which the cationic side-chain containing species BPH-364 has IC50 = 180 nM, while the neutral 
species has IC50 = 858 nM. 
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2.4.2 Synthesis and Testing of Novel Bisphosphonates 
Based on the preliminary results described above, we reasoned that it would be of interest 
to synthesize a series of analogs of BPH-715 in which we varied: 1) the nature of the aliphatic 
side-chain connected to the aryl group; 2) the position of the aliphatic side-chain on the ring; 3) 
the nature of the side-chain linker (O or CH2) between the aliphatic and aryl group and 4), the 
nature of the linker (NH, NHCH2, CH2) to the bisphosphonate backbone with in most cases, a 
protonatable/cationic feature being included. We thus synthesized the 25 compounds shown in 
Figure 2.4 and tested each of them for growth inhibition of B. subtilis, B. anthracis Sterne, S. 
aureus and M. smegmatis. ED50 values (in µg/mL) and computed clogP and logD7.4 values are 
shown in Table 2.2, together with corresponding chemical structures. There are several points of 
interest. First, we see that there is activity (in the ~0.6-2 µg/mL) range against B. anthracis 
Sterne, M. smegmatis and B. subtilis, though less so with S. aureus (~13 µg/mL). Second, with 
B. subtilis (where there is a large range in activity) we see that there is a parabolic dependence 
between cell growth inhibition pED50 (= -log10 ED50, µM) values and clogP with a Pearson 
correlation coefficient r = 0.71. The most active compounds have clogP ≈ -5 while the least 
active compounds are either much more polar (since they have very small side-chains) or are 
more hydrophobic (since they have large hydrophobic side-chains). It thus seems likely that the 
two smallest bisphosphonates will have very poor cell penetration and if these compounds are 
excluded from the data set there is now a more linear correlation between activity (pED50) and 
clogP (or logD7.4) with r = 0.80 ± 0.01. Also, as can be seen in Table 2.2, all of the most active 
compounds have fixed (+1) charges on the aromatic group. That is, they are either pyridiniums 
or imidazoliums. This is of interest since in previous work on bisphosphonate inhibition of 
FPPS[27] we found, using solid-state NMR, that bisphosphonates with basic side-chains (such as 
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aminopyridines) bound to FPPS with their side-chains protonated, suggesting the possibility that 
both FPPS as well as HepPPS/OPPS might be being targeted, which could lead to both quinone 
as well as cell wall biosynthesis inhibition. 
We thus next sought to determine which enzymes might actually be being targeted, in 
cells. To do this we used an expressed SaHepPPS (a hetero-dimer) and for comparison, EcOPPS 
(a homo-dimer). Typical dose-response results are shown in Figure 2.3. What is clear from 
Figure 2.3 is that two of the most active compounds in both enzyme inhibition assays are BPH-
715 and BPH-728, compounds that also have potent activity against B. anthracis Sterne, B. 
subtilis as well as M. smegmatis. A key feature for potent activity against HepPPS as well as 
these bacteria is the presence of a long-chain m-substituted pyridinium group. The amino-
pyridine bisphosphonates as well as the aryl-alkyl imidazolium bisphosphonates have lower 
activity against HepPPS, consistent with the cell growth inhibition assay results. We also found 
very potent activity of some compounds against EcOPPS, typical results are shown in Figure 
2.3A. These compounds thus inhibit both SaHepPPS and EcOPPS—but only have activity 
against the gram-positive bacteria. Interestingly, the most active HepPPS, OPPS as well as cell 
growth inhibitors also have very similar overall lengths, corresponding to ~ 13±1 contiguous 
heavy atoms appended to the bisphosphonate C1 backbone carbon. This length corresponds 
closely to the length of the FPP substrate of HepPPS and OPPS, as illustrated in Figure 2.5, 
suggesting that the most potent inhibitors target a long-chain prenyltransferase. However, it is 
also possible that FPPS itself could be inhibited by BPH-728. This might seem surprising since 
FPP is the product of FPPS and not a substrate and would presumably be too big to bind to the 
GPP substrate-binding site. However, in recent work, Park et al.[29] have shown that FPP binds to 
the allosteric site discovered by Jahnke et al.[30] suggesting that (long-chain) FPP isosteres could 
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also inhibit FPPS. We were unable to obtain active SaFPPS (from either of two commercial 
entities) to test this hypothesis, so we tested for human FPPS inhibition by BPH-728 finding an 
IC50=230 nM, which is remarkably similar to that found against HepPPS (100 nM), as well as the 
100 nM for BPH-715 against HsFPPS.[28] In summary then, we find that BPH-728 is a potent 
inhibitor or HepPPS, OPPS as well as FPPS suggesting that its activity in bacteria could be dual 
inhibition of both quinone and cell wall biosynthesis.  
2.4.3 Mechanisms of Action: Quinones, Cell Walls, and Clostridioides difficile 
Based on the results discussed above, we hypothesized that BPH-728 (and other active 
analogs) might target both bacterial HepPPS as well as bacterial FPPS, and we tested this 
hypothesis in four ways. First, if HepPPS inhibition (or that of the corresponding enzymes in 
Bacilli spp.) is important, then it should be possible to effect a rescue (or partial rescue, if 
multiple targets are involved) by growing cells in the presence of menaquinone (MK-4 or MK-
7), an approach that we and others have used previously.[31] [32] Second, if e.g. BsFPPS inhibition 
is important, then it should be possible to effect a growth inhibition rescue (or partial rescue, if 
multiple targets are involved), by growing cells in the presence undecaprenyl or decaprenyl 
phosphate. This is because FPPS inhibition is expected to block both quinone as well as cell wall 
biosynthesis (Figure 2.1) and UP (or the C50 analog, DP) would likely partially rescue cell 
growth inhibition. Third, we hypothesized that a combination MK-4 plus DP rescue would be 
particularly effective. Fourth, we hypothesized that if bacterial FPPS inhibition is important, then 
it might be possible to inhibit the growth of bacteria that lack quinones, because cell wall 
biosynthesis would still be targeted⎯and pathogens such as C. difficile are ideal for testing this 
hypothesis since they lack quinone biosynthesis machinery. C. difficile also lack heme 
biosynthesis enzymes which involve heme prenylation, another potential but heretofore 
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unexplored area of prenyl synthase inhibition. Fifth, we hypothesized that an “upstream” target 
might be involved, so we used the IPP/DMAPP precursor 1-hydroxy-2-methyl-but-2-enyl 4-
diphosphate (HMBPP) to test this hypothesis. Overall, there are, therefore, 10 sets of “rescue 
experiments” to perform and we carried each of these out using a 50 μM “rescue agent” 
concentration: 1) HMBPP; 2) FPP; 3) UP; 4) MK-4; 5) HMBPP + FPP; 6) HMBPP + UP; 7) 
HMBPP + MK-4; 8) FPP + UP; 9) FPP + MK-4 and 10), UP + MK-4. We also carried out 
additional experiments with decaprenyl phosphate (DP) (not UP), but the results were the same 
(data not shown). We chose MK-4 (rather than MK-7) for most experiments since it is more 
soluble, but results with MK-7 were basically the same (data not shown). 
We first added a menaquinone (MK-4) to B. subtilis cells and measured growth in the 
presence of different concentrations of BPH-728 to determine if this quinone “rescued” cells 
from the growth-inhibitory effects of BPH-728. Results are shown in Figure 2.6 and Table 2.3 
and indicate that cell growth inhibition is indeed rescued by MK-4, the ED50 values for cell 
growth inhibition by BPH-728 increasing by a factor of ~5. This quinone-rescue effect is 
consistent with 81 inhibiting quinone biosynthesis via HepPPS and/or FPPS. In a second 
experiment, we added undecaprenyl phosphate which is also expected to (partially) rescue cells 
from FPPS inhibition. There was, once again, a large (~7x) increase in the ED50 value for cell 
growth inhibition, consistent with FPPS as a second target. Also, addition of MK-4 plus UP 
resulted in a ~25x increase in IC50, Figure 2.6A. That is, BPH-728 is a multi-target inhibitor that 
appears to inhibit both HepPPS as well as FPPS. We also found that addition of FPP (at 50 μM) 
had, as expected, a significant effect on growth inhibition with a 3.5x increase in ED50, Figures 
2.6B, C and Table 2.3. This increase is, perhaps, smaller than might be expected for a compound 
that should rescue both cell wall as well as quinone biosynthesis. However, both MK-4 (MK-7) 
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and UP are for more hydrophobic than FPP and are likely to concentrate in the cell membrane—
which is where they actually function (in electron transfer or in peptidoglycan biosynthesis)—
while the more polar FPP needs to be transported into cells as well as be processed (HepPPS or 
UPPS), so its efficacy is less than with MK-4 or UP. The combinations FPP+UP and FPP+MK-4 
had larger effects (8.9x and 11x, respectively than either agent alone), though again smaller than 
using UP + MK-4 (~25x). 
It is also possible that there might be other targets for BPH-728 such as MenA, UPPS, 
UPPP or a target upstream of FPPS. However, we found no inhibition of UPPS and a 66 μM IC50 
for UPPP inhibition and previously we reported that MenA was only weakly inhibited by the 
BPH-728 analog BPH-715[33], to be compared with the 100 nM inhibition of HepPPS and 
230nM inhibition of FPPS. Upstream inhibition also seems less likely since there was only a ~2x 
increase in ED50, Figures 2.6B, C and Table 2.3, but there was a 8.9x increase with HMBPP + 
MK-4, 6.4x for HMBPP + FPP though only 4.2x with HMBPP + UP. So, HMBPP does 
potentiate the rescue effects seen with FPP and MK-4, but not the effects of UP, due perhaps to 
an effect on transport of UP into the cells. 
To further test our multi-targeting hypothesis, it appeared to be of interest to investigate 
the extent of growth inhibition of a bacterium that does not utilize quinones in electron 
transfer/ATP biosynthesis, since then there would be no HepPPS to inhibit. One such organism is 
C. difficile which utilizes a complex of ferredoxins and flavoproteins to generate a Z gradient 
that drives ATP synthesis via a Na+-ATP synthase.[34] [35] The organism lacks long-chain prenyl 
synthases such as HepPPS or OPPS, as well as downstream quinone biosynthesis enzymes like 
MenA or UbiA, and has just a single trans-prenyltransferase, FPPS, used in cell wall 
biosynthesis. Moreover, C. difficile lacks heme O synthase, the prenyltransferase[34] that 
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farnesylates heme B in many bacteria, which is then oxidized to heme A.[36] We thus tested a 
series of potential inhibitors including BPH-728 against two strains of C. difficile (ATCC 43255 
and ATCC 1870). The compound with the most potent activity against both strains was BPH-728 
with an MIC of 16 µM (6.8 µg/mL) and since all the other potential targets discussed above are 
absent, this strongly indicates that FPPS is the major BPH-728 target in C. difficile. So, when all 
of the results described above are considered, we conclude that HepPPS and FPPS are major 
targets for lipophilic bisphosphonates such as BPH-728 in the pathogens S. aureus and B. 
anthracis Sterne, and in B. subtilis, while only FPPS is targeted in C. difficile. 
2.4.4 Comparison between Results with Gram Positive and Gram-Negative Bacteria 
As to the bisphosphonate features that contribute to activity or inactivity in gram-positive 
or gram-negative bacteria: it appears that for activity against gram-negative bacteria, FPPS is an 
important target as reflected in the ~100-200 nM activity by BPH-1625 against e.g. EcFPPS and 
P. aeruginosa FPPS[12], and by increased EC50 values in cells that overexpress FPPS.[12] These 
compounds have an aryl-alkyl-aryl-bisphosphonate motif (e.g. BPH-210; BPH-1625), but poor 
activity against gram-positive bacteria.[12]  We suggest this is due—at least in part—to an 
uptake/efflux problem since based on structure/sequence similarities, there are no obvious 
differences between e.g. EcFPPS and SaFPPS X-ray structures. With the alkyl-aryl 
bisphosphonates such as BPH-715 and BPH-728, the opposite trend is seen. That is, these 
compounds inhibit gram-positive but not gram-negative bacteria and there is good evidence for 
inhibition of HepPPS as well as FPPS. The primary difference between the two inhibitor types is 
that the new compounds lack terminal aryl groups, which appear to be required for gram-




2.4.5 Crystallographic Investigations 
There are currently no reported X-ray structures of either SaHepPPS or EcOPPS with 
bound inhibitors, the only exception being, arguably, that of the S-thiolo analog of FPP (FSPP) 
bound to EcOPPS (PDB ID code 3WJN), FSPP being a non-reactive substrate-analog. We thus 
sought to investigate how inhibitors might bind to HepPPS and OPPS, but we were unable to 
obtain SaHepPPS structures with any bound inhibitors, or of the most potent EcOPPS inhibitors. 
We did, however, obtain structures of the bisphosphonate BPH-629 (PDB ID code 5ZLF) bound 
to EcOPPS. Full data acquisition and refinement details are given in Table 2.4. Activity against 
EcOPPS was weak, ~330 µM for BPH-629, but the structure is still of interest since it does 
represent the first structure of any long-chain bacterial prenyltransferase with bound inhibitors, 
and could facilitate the design of novel leads. EcOPPS has structural similarity to FPPSs (both 
bacterial and human) as well as GGPPS and SaHepPPS, where the C root mean square 
deviation (rmsd) between EcOPPS (PDB ID code 3WJN) and SaHepPPS (PDB ID code 5H9D) 
is 1.61 Å over 280 aligned residues. The C rmsd for EcOPPS versus Trypanosoma brucei FPPS 
with a bound bisphosphonate inhibitor (BPH-210) is 1.69 Å over 245 residues (PDB ID code 
1RQJ), and 2.38 Å over 244 residues versus Saccharomyces cerevisae GGPPS with BPH-629 
bound (ScGGPPS; PDB ID code 2E93), Figure 2.7. In GGPPS, there are four sites to which 
inhibitor/substrate/product groups can bind: the allylic substrate diphosphate/bisphosphonate 
inhibitor site a; the allylic substrate side-chain site b; the homoallylic diphosphate binding site c, 
and a hydrophobic product (GGPP) sidechain site d. Ligands can thus bind as follows: ab; ad; 
bc or cd. With BPH-629 bound to GGPPS, Figures 2.7A, B two molecules bind, one to site ab 
and one to site cd.[24] We show in Figures 2.7A and 2.7B, alignments of the new EcOPPS/BPH-
629 structure (yellow; PDB ID code 5ZLF) with that of ScGGPPS containing two BPH-629 
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bisphosphonate ligands (blue; PDB ID code 2E93). The single bisphosphonate inhibitor in the 
OPPS structure binds to the same allylic binding site ab as does BPH-629 in ScGGPPS and has a 
very similar conformation, Figure 2.7B. There is no occupancy of the second BPH-629 binding 
site that is found in ScGGPPS. The ab site in EcOPPS corresponds to the FPP-binding site found 
in the X-ray structure of EcOPPS with FSPP, the S-thiolo analog of FPP, Figure 2.7C, and as can 
be seen in Figure 2.7D, the FSPP and BPH-629 inhibitors basically overlap each other. As 
expected, the bisphosphonate binds to the two Mg2+ that are coordinated by two aspartates in the 
first aspartate-rich domain. The third Mg2+ seen in some GGPPS and essentially all FPPS 
structures is absent due, perhaps, to pH/crystallization conditions. And while we do not yet have 
the structure of BPH-728 bound to either EcOPPS or SaHepPPS, the BPH-629 ligand-bound 
EcOPPS structure is remarkably similar to that of the lipophilic bisphosphonate BPH-703, bound 
to the bifunctional Plasmodium vivax farnesyl/geranylgeranyl diphosphate synthase (PvGGPPS; 
PBD ID code 3RBM), Figures 2.7E and 2.7F, strongly suggesting that BPH-728 will bind in a 
similar manner in SaHepPPS and EcOPPS. 
 
2.5 Conclusions & Summary 
The results we have presented above are of interest since they represent the discovery of 
several inhibitors of bacterial long-chain prenyl synthases, enzymes that are essential for quinone 
biosynthesis and are thus anti-bacterial targets. The most potent compounds have IC50 values in 
the 10-100 nM range and some had quite potent activity against Bacillus anthracis Sterne, C. 
difficile, M. smegmatis and B. subtilis as well as modest activity against S. aureus. Cell growth 
inhibition was partially rescued by menaquinone-4, as well as by decaprenyl and undecaprenyl 
phosphates, consistent with the targeting of isoprenoid biosynthesis enzymes (HepPPS and/or 
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FPPS). Activity against C. difficile was of particular interest since this organism lacks quinone 
biosynthesis machinery.  
We also solved the first structures of a long-chain prenyltransferase, EcOPPS, with bound 
inhibitor (a bisphosphonate). The inhibitor binds to the allylic site seen in yeast GGPPS, and the 
malaria parasite F/GGPPS. Overall then, we conclude that some lipophilic bisphosphonates may 





2.6 Figures and Tables 
 
Figure 2.1 Schematic illustrations of some of the enzymes involved in bacterial cell wall and 
quinone biosynthesis in bacteria together with chemical structures of substrates and 
intermediates and sites of action of some inhibitors (red) and “rescue” agents (green). (a) 
Enzymes, products inhibitors and rescue agents (b) Chemical structures of selected enzyme 









Table 2.1 EC50 values of candidate compounds against growth of 9 bacteria (S. aureus, B. 
subtilis, B. anthracis Sterne, M. smegmatis, E. coli, A. baumannii, K. pneumoniae, P. aeruginosa 
and C. albicans) 
EC50 (µM) Sa Bs Ba Ms Ca Ec Ab Kp Pa 









>50 >67 >67 >67 
364 36 ± 9.5 
17 ± 
 2.3 
10 ±  
5.0 
>67 >150 >50 >67 >67 >67 
642 130 ± 87 110 ± 42 >130 >67 >150 >50 >67 >67 >67 
981 110 ± 33 3.4 ± 1.5 
2.1 ± 
0.071 
>67 31 ± 4.2 >50 >67 >67 >67 
629 
19 ±  
14 




>67 >150 >50 >67 >67 >67 
1463 18 ± 8.7 
1.1 ± 
0.068 


















Miconazole  / / / / 
1.5 ± 
0.078 
/ / / / 
Vancomycin  / / 
2.6 ± 
0.21 
/ / / / / / 
 
*Gentamycin is the antibiotic control for S. aureus, B. subtilis, M. smegmatis, E. coli, A. 
baumannii, K. pneumoniae, P. aeruginosa. Miconazole is the antibiotic control for B. anthracis 
Sterne. Vancomycin is the antibiotic for C. albicans. 
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Figure 2.3B Typical dose-response curves for SaHepPPS inhibition. The most potent inhibitors 
also have potent activity (~10-20 nM) against EcOPPS (Figure 2.3A), but were not active against 
E. coli or other gram-negative bacteria.  
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Table 2.2 Bacterial cell growth inhibition by bisphosphonates, cLogP and LogD7.4 of all 





























1.7 1.8 26 1.4 440 -2.08 -5.65 
1662 
 
2.1 0.6 13 6.1 220 -0.50 -4.07 
1642 
 
2.2 2.1 13 5.9 460 -1.14 -4.71 
1661 
 
2.4 0.8 13 5.5 440 -2.50 -6.07 
1660 
 
2.8 0.4 18 6.2 510 -1.52 -5.09 
1655 
 
3.1 2.2 21 7.2 700 -1.14 -4.71 
728 
 


































3.6 2.4 51 10 1100 -2.46 -6.25 
1663 
 
4.2 1.9 14 6.8 670 -2.50 -6.07 
1650 
 
4.6 4.3 34 15 420 -2.50 -6.07 
1656 
 
5.5 2.2 30 7.2 48 -0.08 -3.65 
1654 
 
5.7 2.5 28 150 1000 -2.25 -5.82 
1664 
 
7.0 1.1 31 70 1000 -1.52 -5.08 
1648 
 


































21 3.2 35 75 1200 -0.51 -3.10 
1647 
 
21 7.4 36 150 2000 0.48 -2.12 
1653 
 
26 3.0 32 93 1100 -0.24 -2.00 
1651 
 
36 5.0 22 91 2000 -0.27 -3.48 
1649 
 




75 4.2 60 200 1000 -0.52 -2.24 
1645 
 
97 2.3 230 290 89 -3.73 -6.35 
1646 
 



































110 2.5 69 79 1300 1.20 -1.63 
1641 
 
180 11 52 100 ND 0.77 -2.31 
1652 
 









Figure 2.5 Cartoon illustration of the similarity between a putative FPP transition state/reactive 




Figure 2.6 Effects of MK-4, UP, HMBPP and FPP as well as pairwise combinations on B. 
subtilis growth inhibition by BPH-728. a) Effects of MK-4, UP and MK-4 plus UP on growth 
inhibition by BPH-728. b) Effects of HMBPP, FPP with or without MK-4 or UP as well as 
HMBPP + FPP on BPH-728 inhibition of B. subtilis cell growth. All rescue agents were at 50 
μM. c) Schematic illustration of the x-fold rescues by compounds or pairs of compounds on B. 
subtilis growth inhibition by BPH-728. The largest effect (25x) is found with UP (50 μM) + MK-
4 (50 μM). Cell growth inhibition assays were carried out in duplicate. The largest effects (~>9x) 
are seen with MK-4 or UP combinations and are colored cyan. 
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Table 2.3 Effects of MK-4, UP, HMBPP and FPP as well as pair-wise combinations on B. 
subtilis cell growth inhibition by 81. All ED50 values are in μg/mL. All compounds were present 
at 50 μM. “Rescue-fold” means ED50 (+ rescue agent)/ED50 (minus rescue agent). All ED50 




Table 2.4 Data Collection and Refinement Statistics for EcOPPS. 
                                                                EcOPPs_629 EcOPPs_981 
PDB code 5ZLF 5ZE6 
Data co1lection   
space group C2 P212121 
unit-cell   
a [Å] 149.34 94.03 
b [Å] 46.65 111.99 
c [Å] 215.74 133.82 
α /β /γ (°) 90/101.08/90 90/90/90 
resolution [Å] 25-2.85 (2.95-2.85) 25-2.50 (2.59-2.50) 
unique reflections 34599 (3427) 49730 (4902) 
redundancy 4.3 (4.4) 5.8 (5.9) 
completeness [%] 99.9 (100.0) 100.0 (100.0) 
average I/σ(I) 15.6 (2.37) 22.29 (4.8) 
R merge [%] 7.2 (58.2) 9.7 (49.5) 
   
Refinement   
no. of reflections 34589 (2500) 47239 (3516) 
R work (95% of data) 0.241 (0.324) 0.185 (0.228) 
R free (5 % of data) 0.299 (0.366) 0.264 (0.349) 
r.m.s.d. bonds [Å] 0.009 0.010 
r.m.s.d. angles [º] 1.59 1.49 
dihedral angles   
most favored [%] 93.6 97.9 
allowed [%] 6.3 2.1 
disallowed [%] 0.1 0.0 
no. of non-H atoms / 
average B [Å2 ]  
  
protein 8626 (103.48) 9413 (42.3) 
water 6 (53.9) 417 (39.2) 
Ligand 30 (123.4) 50 (63.8) 
ion 2 (72.8) 2 (37.1) 
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Figure 2.7 Structure of BPH-629 bound to EcOPPS and a comparison with S. cerevisae GGPPS 
and P. vivax F/GGPPPS ligand-bound structures. A) Structure superimposition EcOPPS•BPH-
629 (PDB ID code 5ZLF) with ScGGPPS•BPH-629 (PDB ID code 2E93). b) Superimposition of 
BPH-629 ligands shown in b). c) Superimposition of EcOPPS•BPH-629 with EcOPPS•FSPP 
(PDB ID code 3WJN). d) Superimposition of BPH-629 and FSPP ligands from d). e) 
Superimposition of EcOPPS•BPH-629 with P. vivax—F/GGPPS•BPH-703 (PDB ID code 
3RBM). F) Superimposition of BPH-629 and BPH-703 ligands from e). BPH-629 binds to just 
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The burden of resistance to currently available antibiotics necessitates the development of 
new antibacterial agents, a significant threat given their ability to evade many antibiotics and the 
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host immune response. The bacterial pathogens commonly associated with antimicrobial 
resistance include Enterococcus faecium, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacter spp.  
Vancomycin-resistant enterococci (VRE), in particular isolates of Enterococcus faecalis 
and Enterococcus faecium, are of particular concern and have been identified as leading sources 
of nosocomial infections.[1] Enterococcal infections were initially susceptible to many 
therapeutic agents including β-lactams (in particular ampicillin), glycopeptides (vancomycin), 
fluoroquinolones, and aminoglycosides.[2] However, the ability of enterococci to colonize the 
gastrointestinal tract of patients hospitalized for long periods has permitted these organisms to 
acquire resistance, particularly after repeated drug exposure,[1] severely limiting the number of 
effective therapeutic options available. Moreover, VRE strains have been isolated that exhibit 
resistance to newer antibacterial agents, including linezolid and daptomycin.[3] [4] The problem of 
antibiotic resistance is compounded by the diminishing number of new antibiotics being 
approved. 
Our collaborator groups (Sellem and Cushman groups) recently explored the 
antimicrobial activity of a broad range of phenylthiazole aminoguanidines against drug-resistant 
staphylococci, [5]–[9]  three of which (1−3, Figure 3.1) we find have potent activity against both E. 
faecalis and E. faecium. In this chapter, I will mainly discuss the examination of the activity of 
these compounds against clinical isolates of VRE, and their mechanisms of action. 
3.3 Material & Methods  
3.3.1 Synthesis of Thiazole Compounds 1−3. 
Synthetic schemes, spectral data, and purity (>95%, determined by HPLC) of compounds 





3.3.2 Bacterial Strains and Reagents Used. 
Clinical isolates of E. faecalis and E. faecium were obtained through BEI Resources 
(Table 3.2) Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter cloacae were obtained from the American Type Culture Collection (Manassas, 
VA, USA). Escherichia coli OP50, E. coli 1411, and E. coli ΔAcrAB were described before.[10] 
[11] The human colorectal cell line (HRT-18) was obtained from the American Type Culture 
Collection (Manassas, VA, USA). Ampicillin (IBI Scientific, Peosta, IA), chloramphenicol 
(Sigma- Aldrich, St. Louis, MO, USA), ciprofloxacin (Enzo Life Sciences, Farmingdale, NY, 
USA), doxycycline monohydrate (Alfa Aesar, Ward Hill, MO, USA), linezolid (Chem-Impex 
International Inc., Wood Dale, IL, USA), and vancomycin hydrochloride (Gold Biotechnology 
Inc., St. Louis, MO, USA) were from the vendors noted above. Compounds were then dissolved 
in dimethyl sulfoxide (DMSO) (for ampicillin, doxycycline, linezolid, and vancomycin), ethanol 
(for chloramphenicol), or 0.1 N HCl (for ciprofloxacin), in order to prepare stock solutions (10 
mg/mL). Tryptic soy broth (TSB), tryptic soy agar (TSA), and brain heart infusion broth (BHI) 
were purchased from Becton Dickinson and Company (Franklin Lakes, NJ, USA). Phosphate-
buffered saline (PBS) (Sigma-Aldrich, St. Louis, MO, USA), RPMI-1640 medium (American 
Type Culture Collection, Manassas, VA, USA), and 96-well plates (CellTreat Scientific 





3.3.3 Determination of Minimum Inhibitory Concentration (MIC) and Minimum 
Bactericidal Concentration (MBC). 
The MICs of thiazole compounds 1−3 and control antibiotics (linezolid, vancomycin) 
were determined against all bacterial strains tested using a broth microdilution method, following 
the guidelines outlined by the Clinical and Laboratory Standards Institute as described 
elsewhere.[9] Strains of E. faecalis, A. baumannii, E. cloacae, E. coli, and P. aeruginosa were 
cultured in TSB, while E. faecium strains were cultured in BHI. For Gram-negative bacterial 
strains, the MIC was also tested in the presence of a subinhibitory concentration (1/4 × MIC) of 
colistin (to permeabilize the outer membrane). Plates containing test agents and bacteria were 
incubated at 37 °C for 18−22 h prior to determining the MIC. The MIC was taken to be the 
lowest concentration of each test agent where bacterial growth could not be visualized. 
The MBC for each test agent against E. faecalis and E. faecium was determined using 
methods described previously,14 with the following modifications. Aliquots (5 μL) of E. faecalis 
were transferred to TSA plates, while aliquots of E. faecium were transferred onto BHI agar 
plates. Plates were incubated at incubated at 37 °C for 18−22 h before the MBC, the 
concentration where >99% reduction in bacterial cell count was observed, was determined. 
3.3.4 Time-Kill Analysis of Compounds 1−3 and Linezolid against VRE. 
Vancomycin-resistant E. faecalis ATCC HM-201 and vancomycin-resistant E. faecium 
ATCC 700221 cells in late logarithmic growth phase were diluted to ∼5 × 106 colony-forming 
units (CFU)/mL and (in triplicate) exposed to concentrations equivalent to 4 × MIC of 1− 3 or 
linezolid in either TSB (for E. faecalis) or BHI (for E. faecium). Then 100 μL samples were 
collected after 0, 2, 4, 6, 8, 10, 12, and 24 h of incubation at 37 °C and subsequently serially 
diluted in PBS. Bacteria were then transferred to either TSA (for E. faecalis) or BHI agar plates 
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(for E. faecium) and were incubated at 37 °C for 18−22 h before viable CFU/mL values were 
determined. 
3.3.5 Bacterial Cytological Profiling of Phenylthiazole Compounds against Bacillus subtilis 
and Escherichia. coli. 
Cells were grown in Luria−Bertani (LB) medium at 30 °C (E. coli) or 37 °C (B. subtilis) 
until the optical density at 600 nm (OD600) was ∼0.2. Cells were then left untreated, treated 
with compounds, or treated with compounds in the presence of 0.5 M sucrose (E. coli) or MSM 
(B. subtilis), as described previously.[12] [13] [14] After 30 min or 2 h, cells were stained with FM 
4−64 (1 μg/mL) to visualize the membranes, DAPI (2 μg/mL E. coli, 1 μg/mL B. subtilis) to 
visualize the DNA, and SYTOX Green (1 μg/mL), a vital stain which is normally excluded from 
cells with an intact membrane but brightly stains cells that are lysed.[14] Images were collected 
using a Delta Vision Spectris Deconvolution microscope as described previously.[14] 
3.3.6 Inhibition of Cell Wall Synthesis in Enterococci by Compound 1 via UDP-N-
acetylmuramyl-pentapeptide Accumulation. 
To investigate whether the phenylthiazole compounds exhibit their effect on enterococci 
by inhibiting cell wall synthesis, we determined the accumulation of the final soluble cell wall 
precursor (UDP-N-acetylmuramyl-pentapeptide) inside bacterial cells. We used the procedure 
described previously[15] with the following modifications: E. faecalis NR-31975, in early 
logarithmic growth stage (OD600 ∼ 0.5), was incubated with 130 μg/mL chloramphenicol for 15 
min at 37 °C. Bacteria were subsequently incubated with either 10 × MIC of compound 1 or 
vancomycin (positive control) for 30 min at 37 °C. Untreated samples served as a negative 
control. Samples were then centrifuged at 12000g, the supernatant discarded, and the pellet 
resuspended in 1 mL of sterile deionized water. The cell pellet was boiled at 100 °C for 30 min 
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before samples were chilled on ice for 10 min. UDP-N-acetylmuramyl-pentapeptide levels were 
measured using an Agilent High Performance liquid chromatograph coupled to a time- of-flight 
mass spectrometer (HPLC-MS). A Waters XBridge Phenyl (2.1 mm × 100 mm, 3.5 um) column 
was used, with mobile phases of water, 0.1% formic acid (buffer A) and acetonitrile, 0.1% 
formic acid (buffer B). A gradient of 5−20% buffer B over 14 min was then employed at a flow 
rate of 0.3 mL/min, with an electrospray source in positive ionization mode. Extracted ion 
chromatograms (EICs) were generated at a m/z of 1150.3588 (20 ppm window). The mass error 
for UDP-N-acetylmuramyl-pentapeptide was less than 1 ppm. 
3.3.7 Molecular Target Identification Using Genomic Insertion of a Transposon with a 
Strong Outward-Oriented Promoter. 
Overexpression of the target/resistance mechanism was carried out using a transposon 
with a strong outward-oriented promoter for the random overexpression of neighboring genes in 
Bacillus subtilis. The pEP26 delivery vector carrying the transposon with the promoter 
(TnHyJump) was transformed into B. subtilis, as described elsewhere.[16] For transposon 
integration into bacterial DNA, cells were grown for 10 h at 25 °C, serially diluted, subcultured 
in dual-selection TSA plates containing 5 μg/mL chloramphenicol (for transposon selection) and 
3 × MIC compound 1 (for selection of compound resistance), and then incubated overnight at 
42 °C. Growth at 42 °C is nonpermissive for the maintenance of the delivery vector, so 
chloramphenicol/compound 1 resistance arises mainly from the chromosomal insertion of the 
transposon. Twelve colonies out of 142 colonies on 3 × MIC compound 1 were screened for 
MIC shift (resistance) against compound 1 using the broth microdilution method to confirm 
resistance. Genomic DNA was extracted from resistant colonies (recombinants that were capable 
of growth at concentrations that were inhibitory to the control) and were sent to the Purdue 
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Genomics Core Facility for sequencing. Insertion sites were identified by sequencing. 
Transposon location within the resistant B. subtilis genome, orientation, and flanking genes were 
determined by performing a BLASTN search on the NCBI public BLAST server. 
3.3.8 HsFPPS, EcUPPS, and EcUPPP Inhibition Assays. 
Human FPPS and E. coli UPPS and UPPP (denoted EcUPPS and EcUPPP) were 
expressed, purified, and assayed as described previously.[17] [18] [19] Briefly, compound 1 was 
prepared as a 20 mM stock solution in DMSO and then serially diluted from 200 to 0.2 μM. 
EcUPPS (0.028 μM) was incubated with compound 1 at room temperature for 30 min in HEPES 
buffer (100 mM HEPES, 50 mM NaCl, 0.5 mM MgCl2, 0.02% DDM (w/v), pH 7.5) before 
adding the reaction mixture with 10 μM IPP and FPP and 0.375 U/mL inorganic phosphatase. 
The 100 μL reaction was quenched by the same volume of malachite green mixture from a 
malachite green phosphate assay kit (BioAssay Systems). For the EcUPPP inhibition assay, the 
20 mM stock solution of compound 1 was serially diluted from 300 to 0.8 μM. Compound 1 was 
incubated with 0.125 μM EcUPPP at room temperature for 15 min in HEPES buffer (50 mM 
HEPES, 150 mM NaCl, 10 mM MgCl2, 0.02% DDM (w/v), pH 7.5), followed by the addition of 
35 μM FPP and incubation at 37 °C for 20 min. The 100 μL reaction was then mixed with the 
same volume of the malachite green mixture. The released phosphate in EcUPPS and EcUPPP 
assays was monitored by absorbance at 620 nm after 30 min development. Dose response curves 
were constructed using GraphPad Prism (Graphpad Software, San Diego, CA). 
3.3.9 Uncoupler Assays. 
Proton translocation out of E. coli inverted membrane vesicles (EcIMVs) was measured 
by the fluorescence increase of ACMA. The excitation and emission wavelengths were 410 and 
480 nm, respectively. IMVs (0.1 mg/mL membrane protein), 2 μM ACMA, and 0.5 mM ATP/ 
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succinate were added in HEPES buffer (10 mM HEPES-KOH, 5 mM MgSO4, 100 mM KCl, pH 
7.5). The uncoupler CCCP and compound 1 were serially diluted in the reaction mixture. Dose 
response curves were constructed using GraphPad PRISM (Graphpad Software, San Diego, CA). 
3.4 Results & Discussions 
3.4.1 Antibacterial Activity of Compounds 1−3 Against the ESKAPE Pathogens 
(Enterococcus faecium, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa, and Enterobacter spp.). 
We first investigated the antibacterial activity of phenylthiazole compounds 1−3 against a 
panel of ESKAPE pathogens using the broth microdilution method. Examination of the spectrum 
of activity of 2 and 3 revealed that they were inactive against most Gram-negative pathogens 
(minimum inhibitory concentration, MIC > 128 μg/mL), Table 3.1, the exception being with A. 
baumannii where the MIC was 8 μg/mL, similar to that found with erythromycin. Compound 1 
also exhibited limited activity against the same pathogens (MIC ranges from 8 to 64 μg/mL), 
indicating that all three compounds are generally ineffective against Gram-negative bacteria. 
These results are in contrast to our earlier results on S. aureus, differences that could be due to 
the presence of the outer membrane (OM) in the Gram- negative bacteria and/or efflux pumps. 
We thus next investigated whether the presence of the OM and/or efflux pumps did in fact 
contribute to the lack of antibacterial activity observed for 1−3 against Gram-negative bacteria. 
In the presence of a subinhibitory concentration of the membrane-disrupting antibiotic 
colistin, which permeabilizes the outer membrane, the MIC of compounds 1−3 against Gram-
negative bacteria decreased dramatically. For example, 2 and 3 were inactive against K. 
pneumoniae, P. aeruginosa, and E. coli when tested alone (MIC > 128 μg/mL), but in the 
presence of subinhibitory levels of colistin, both compounds exhibited potent antibacterial 
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activity (MIC from 1 to 4 μg/ mL). This behavior is similar to that seen with the antibiotic 
erythromycin, whose activity is known to be impeded by the presence of the OM. For example, 
with K. pneumoniae, P. aeruginosa, and E. coli, we find that erythromycin alone lacks activity 
(MIC > 128 μg/mL), but in the presence of colistin, erythromycin has potent activity against 
each organism (MIC from 0.5 to 1 μg/mL). It thus appears likely that the OM impedes the entry 
of both the phenylthiazole compounds as well as erythromycin into Gram-negative bacteria. 
When the antibacterial activity of compounds 1−3 was examined against E. coli 1411 and 
a mutant strain containing a deletion of the gene encoding the AcrAB efflux pump, there was a 
major decrease in the MIC in the mutant. Against E. coli 1411, compound 1 inhibited growth at 
64 μg/mL, and compounds 2 and 3 were inactive (MIC > 128 μg/mL). However, against the 
mutant strain (Escherichia coli 1411 ΔacrAB), all three compounds were potent inhibitors of 
bacterial growth (MIC of 4 μg/mL). This behavior is similar to that observed with linezolid, a 
known substrate of the AcrAB efflux pump.[20] It thus appears that the lack of activity of the 
phenylthiazoles against Gram-negative bacterial pathogens is due both to the presence of the OM 
as well as drug efflux pumps. Fortunately, in earlier work, we found that compounds 1−3 
exhibited potent antibacterial activity against the Gram-positive pathogen, methicillin-resistant S. 
aureus (MIC values ranged from 1.3 to 5.6 μg/mL),[5] and as shown in Table 3.1, all three 
compounds are potent inhibitors of the growth of another important Gram-positive pathogen, 
vancomycin-resistant E. faecium (MIC = 0.5 μg/mL). Thus, the phenylthiazole compounds 
appear to be potent leads against clinically relevant Gram-positive pathogens, including MRSA 
and VRE. Plus, the fact that they synergize with cell wall biosynthesis inhibitors in S. aureus 




3.4.2 Phenylthiazole Compounds Retain Their Potent Activity against Clinical Isolates of 
Drug-Resistant Enterococci. 
To further evaluate the antibacterial activity of compounds 1−3 against enterococci, we 
determined MIC values against 24 strains of E. faecalis and E. faecium (including 16 strains 
resistant to vancomycin), isolated from diverse sources including blood, urine, peritoneal fluid, 
sputum, and feces (Table 3.2) from infected patients. All three compounds exhibited potent 
antibacterial activity against all isolates tested (Table 3.3). Interestingly, 1−3 were most active 
against isolates of vancomycin-resistant E. faecium, inhibiting growth at concentrations ranging 
from 0.5 to 4 μg/mL (Table 3.4). 
We next investigated whether the antibacterial effects were bacteriostatic or bactericidal. 
To address this, we determined the minimum bactericidal concentrations, MBCs. Against most 
strains of E. faecalis and E. faecium, the MBC values were equal to or one-fold higher than the 
MIC values for compounds 1 and 3, indicating that the two compounds are bactericidal. A 
similar trend was observed for compound 2 against E. faecalis; however, against E. faecium, the 
MBC for 2 was more than 4- fold higher than the MIC, indicating 2 may be bacteriostatic, 
particularly against vancomycin-resistant isolates. As expected, ampicillin exhibited bactericidal 
activity against enterococci strains sensitive to this antibiotic, while linezolid exhibited. 
bacteriostatic activity against both E. faecalis and E. faecium (MBC was more than 4-fold higher 
than the MIC). 
3.4.3 Compounds 1 and 3 Rapidly Eradicate Vancomycin-Resistant Enterococci as 
Determined by Time-Kill Analysis. 
To confirm the bactericidal activity of the phenyl-thiazole compounds against VRE, we 
carried out time-kill assays. As shown in Figure 3.2, compounds 1 and 3 exhibited rapid 
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bactericidal activity against both vancomycin-resistant E. faecium as well as vancomycin-
resistant E. faecalis. Compound 1 (at 4 × MIC) was capable of completely eradicating both 
strains of VRE within 2 h, and no bacterial regrowth was observed over the following 22 h. 
Compound 3 matched compound 1 in completely eliminating vancomycin-resistant E. faecalis 
within 2 h (Figure 3.2B) but required 4 h to achieve the same effect against vancomycin-resistant 
E. faecium (Figure 3.2A). Compound 2 also exhibited rapid bactericidal activity against E. 
faecalis, completely eradicating bacterial growth within 2 h. However, although 2 produced a 
gradual reduction in CFU against vancomycin-resistant E. faecium after 24 h, the compound was 
not capable of completely eradicating the bacteria. This supports the MBC results for 2 against 
vancomycin-resistant E. faecium, indicating that 2 is bacterio- static. The bacteriostatic activity 
of linezolid against both E. faecium and E. faecalis is also confirmed because the antibiotic was 
not able to generate a 103 × reduction in VRE CFU over 24 h. 
3.4.4 Compound 1 Exerts Its Antibacterial Activity by Inhibiting Cell Wall Synthesis. 
To investigate the mechanism of action of the phenylthiazoles, compound 1 was 
subjected to bacterial cytological profiling (BCP) in represen- tative Gram-positive (Bacillus 
subtilis) and Gram-negative (E. coli) bacteria. BCP identifies the likely pathway targeted by 
novel antibiotics by comparing their cytological effects with those found using a library of 
cytological profiles generated by using antibacterials with known mechanisms of action (MOAs) 
or by the rapid proteolytic depletion of essential proteins.[12] [13] [14] When E. coli ΔtolC (which 
lacks an effective efflux pump) was treated with compound 1, cells lysed and formed 
spheroplasts after 2 h (Figure 3.3). Spheroplasts and misshapen cells were very prevalent in the 
presence of 0.5 M sucrose, which osmotically stabilizes cells lacking a functional cell wall. Lysis 
and cell shape defects were observed as early as 30 min after addition of compound 1 to the 
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medium. In contrast, cells incubated with the cell wall biosynthesis inhibitor D-cycloserine 
formed misshapen cells and spheroplasts after 30 min (Figure 3.3), and cells were completely 
lysed after 2 h (data not shown). These results suggest that compound 1 inhibits cell wall 
biosynthesis in E. coli ΔtolC. 
To determine whether 1 had the same effect in a Gram- positive bacterium, we examined 
the effects of 1 in B. subtilis, again using BCP. B. subtilis incubated with 1 at 5 × MIC rapidly 
lysed, with 95% (n = 131) of cells being permeable to Sytox Green (a nucleic acid stain that is 
impermeable to live cells) within 30 min of treatment. Because disruption of either the cell wall 
or the cell membrane can result in permeabilized cells (Figure 3.4), we next investigated the 
effects of 1 with control agents in the presence of dimethylsulfone (aka methylsulfonyl methane, 
MSM), which osmotically stabilizes cells for better observation of cell shape defects. Cells 
treated with 1 for 2 h in the presence of MSM were slightly misshapen or bent and contained 
pools of membrane (Figure 3.5 and Figure 3.6). Figure 3.6 shows four examples of cells 
containing a small bulge at the site of the bend that could be visualized with phase contrast 
microscopy. These cells appeared very similar to vancomycin-treated cells, which also show 
subtle cell shape-defects, forming bends, bulges, and pools of membrane (Figure 3.5 and Figure 
3.6). Unlike compound 1 and vancomycin, D-cycloserine generated very obvious cell shape 
defects (Figure 3.5), and Triton X-100 detergent-treated cells were lysed without affecting 
overall cell shape. MSM suppresses cell lysis and permeability defects for cell wall active 
antibiotics but not for membrane active compounds (Figure 3.5 and Figure 3.6).[13] We found 
MSM dramatically suppressed the permeability phenotypes of compound 1, as well as 
vancomycin and D-cycloserine, but had no effect on Triton X- 100 treated cells, suggesting that 
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1 inhibits cell wall/ peptidoglycan synthesis (Figure 3.6) in both B. subtilis and E. coli ΔtolC, 
implicating broadly conserved target(s) and MOA. But what are the actual targets of 1? 
3.4.5 Target Identification. 
Peptidoglycan biosynthesis involves numerous enzymes and a simplified metabolic 
pathway is shown in Figure 3.7. The first step involves the sequential addition of two molecules 
of isopentenyl diphosphate (IPP, 4) to dimethylallyl diphosphate (DMAPP, 5) to form the (C15) 
isoprenoid farnesyl diphosphate (FPP, 6) in a reaction catalyzed by farnesyl diphosphate 
synthase (FPPS), with IPP/ DMAPP being produced by the mevalonate pathway in S. aureus and 
the nonmevalonate (methylerythritol phosphate, MEP) pathway in B. subtilis and E. coli. FPP 
then reacts with eight additional IPP molecules to form the (C55) isoprenoid undecaprenyl 
diphosphate (UPP, 7) in a reaction catalyzed by undecaprenyl diphosphate synthase (UPPS). 
UPP is converted to undecaprenyl monophosphate (UP, 8) by undecaprenyl diphosphate 
phosphatase (UPPP), then UP reacts with UDP- N-acetylmuramyl pentapeptide (9) to form lipid 
I (10) in a reaction catalyzed by MraY, followed by conversion to lipid II, and after several more 
steps, peptidoglycan (11) is formed. Drugs such as ampicillin and vancomycin inhibit at some of 
these later stages in cell wall synthesis (transpeptidation), as they interfere with peptidoglycan 
cross-linking, resulting in defects in cell wall structure. We first sought to see if 1 resulted in 
changes in the concentration of UDP-N-acetylmuramyl pentapeptide (compound 9), the final 
soluble cell wall precursor in peptidoglycan biosynthesis, in E. faecalis NR-31975 cells. We 
found that treatment of cells with compound 1 resulted in a similar LC- MS result to treatment of 
cells with vancomycin, a known inhibitor of bacterial cell wall synthesis. This can be seen in the 
results shown in Figure 3.8, in which there are large increases in UDP-N-acetylmuramyl 
pentapeptide accumulation with 1 or vancomycin treatment, implicating inhibition of 
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peptidoglycan biosynthesis. A peak was present in the chromatograms at the same retention time 
(∼8 min) for both 1 and vancomycin-treated samples and had the correct m/ z for the 
pentapeptide, m/z = 1150.3588, a <1 ppm error. These results support inhibition of a target in the 
peptidoglycan biosynthesis pathway, but they do not suggest a specific molecular target. 
We next tried to identify the molecular target of the phenylthiazole 1 by using a target 
overexpression experiment in Bacillus subtilis. The metabolic function(s) in B. subtilis inhibited 
by the thiazole should in principle be restored by overexpression of the targeted protein(s) via 
genomic insertion of a transposon with a strong outward-oriented promoter. That is, resistance to 
compound 1 should be achieved by overexpression of the drug-resistance gene, which could be a 
molecular target in peptidoglycan biosynthesis but also perhaps an efflux pump. [16] In the 
presence of a high concentration of compound 1, only bacterial colonies where the transposon 
successfully inserts adjacent to the biological target/resistance mechanism survive due to 
overexpression of the target/ resistance mechanism by the bacterium. Using this approach, we 
identified three possible targets: (1) yubA, locus tag BSU31160, a putative inner membrane AI-
2E (autoinducer-2- exporter) family protein, (2) yubB, locus tag BSU31150, undecaprenyl 
diphosphate phosphatase (UPPP), and (3) yubD, locus tag BSU31130, a putative major 
facilitator superfamily transporter. Clearly, these results strongly suggest UPPP as a likely target 
because UPPP is in the peptidoglycan biosynthesis pathway, Figure 3.7. If UPPP (YubB) is 
inhibited by 1, there would be a decrease in UP levels and this would be expected to lead to 
accumulation of the MraY substrate 9 (because it would not have a substrate to react with). 
To test this hypothesis, we used the E. coli UPPP expression system described previously 
[17] [21] and determined the IC50 for inhibition by 1. We found a 6 μM IC50 (corresponding to 2 
μg/ mL), consistent with a UPPP target (Figure 3.9A). We also tested for human FPPS (HsFPPS) 
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and E. coli UPPS (EcUPPS) inhibition. There was no inhibition of FPPS (data not shown), but 
UPPS was inhibited with a 19 μM IC50 (corresponding to 6.3 μg/mL), Figure 3.9B. What is 
interesting here is that UPPS as well as UPPP are both inhibited at low μM levels and because 
these two enzymes are adjacent to each other in the biosynthetic pathway, this multitarget 
inhibition is expected to contribute to their activity, in cells, and is very similar to the dual 
UPPS/UPPP inhibition we have reported with other inhibitors.[21] 
What, then, if anything, is the involvement of YubA and YubD in the activity of 1 in 
cells? At present, these proteins have not been characterized in detail, but both are annotated as 
transporters, raising the question: could the phenythiazoles also target membrane transporters? 
Upon inspection of the structure of 1 (as well as 2 and 3), it is clear that each compound has a 
polar aminoguanidine “headgroup” (pKa ∼ 7) and a lipophilic “tail”. In other work, we and 
others have shown that many such compounds (lipophilic bases) can act as protonophore 
uncouplers, collapsing the proton motive force (PMF) in cells, as determined by using 
fluorescence probes as well as by 31P NMR spectroscopy.[22]–[24] That work led to a reappraisal of 
the mechanism of action (MOA) of the tuberculosis (TB) drug lead SQ109, as well as the MOA 
of TB drugs in clinical use such as bedaquiline and clofazimine.[23] More importantly, many TB 
drug leads that had been thought to target the trehalose monomycolate transporter MmpL3 
(mycobacterial membrane protein large 3) in a direct fashion are now thought to actually 
function by collapsing the PMF, inhibiting the function of PMF-driven transporters. If 1 were to 
also collapse the PMF, this could indirectly inhibit the transporters YubA and YubD, identified 
in the transposon mutagenesis experiments.  
To determine whether 1 is a protonophore uncoupler, we used the E. coli inverted 
membrane vesicle (IMV) system we used previously.[24] Results with 1 and the potent, known 
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uncoupler CCCP (carbonyl cyanide m-chlorophenylhydrazone) are shown in Figure 3.9 C, D 
with both ATP-powered PMF generation as well as succinate/O2-powered PMF generation. The 
IMVs have their ATPase on the outside of the vesicle so ATP hydrolysis through the ATPase, or 
succinate/O2, drives H+ into the vesicles, the fluorophore ACMA (9-amino-6-chloro-2-
methoxyacridine) accumulates, and its fluorescence is self-quenched (the signal goes down). 
Addition of CCCP or 1 collapses the PMF and fluorescence increases (back to normal). For 
CCCP, the EC50 is 0.4 μM in ATP and 0.2 μM in succinate; for 1, the EC50 for PMF collapse is 
12 μM in ATP and 25 μM in succinate, Figure 3.9 C, D. This is relatively weak uncoupling but 
could lead to inhibition of some transporters, including drug efflux pumps. 
At present, the three-dimensional structures of YubA, YubB (UPPP), and YubD have not 
been reported. However, a structural model for UPPP (together with site-directed mutagenesis 
results) for UPPP has been reported[17] and is shown in Figure 3.10, together with RaptorX 
predicted structural models[25] for YubA and YubD, and an X-ray structure for UPPS (PDB 
1X06 [26]). YubA and YubD are both membrane proteins, and the proteins with known structures 
that were used to create these homology models are all transporters, including PMF-driven 
multidrug efflux pumps. We thus propose that 1 inhibits both UPPS and UPPP by directly 
binding to these proteins, in addition to potentially affecting YubA and/or YubD function, by 
acting as a protonophore uncoupler, reducing ΔpH, with such multitargeting contributing to the 
very low rate of resistance that we observe. 
3.5 Conclusions & Summary 
In this study, we demonstrate that three phenylthiazole compounds exhibit potent 
antimicrobial activity in vitro against clinically relevant strains of vancomycin-resistant 
enterococci, inhibiting growth of clinical isolates at concentrations as low as 0.5 μg/mL. The 
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compounds exerted a rapid bactericidal effect, targeting cell wall synthesis. Transposon 
mutagenesis suggested three possible targets: YubA, YubB (undecaprenyl diphosphate 
phosphatase (UPPP)), and YubD. Both UPPP as well as undecaprenyl diphosphate synthase were 
inhibited by compound 1. YubA and YubD are annotated as transporters and may also be targets 
because 1 collapsed the proton motive force in membrane vesicles. Taken altogether, these 
results provide valuable information to be used in the development of this class of compounds as 




3.6 Figures and Tables 








Table 3.1 Minimum inhibitory concentration (MIC) of thiazole compounds 1-3 and control 
antibiotics against the ESKAPE pathogens (excluding S. aureus). For Gram-negative bacteria, 
the MIC in the presence of ¼ × MIC of colistin (COL) was used to examine the impact of the 
outer membrane on negating the antibacterial activity of the compounds. 








































































































































































































































2006 Human secretion Ciprofloxacin and vancomycin 
E. faecalis 
NR-31972 (VRE) 
SF28073 Michigan, USA 2003 Urine 




S613 - 2004 Blood Vancomycin 
E. faecalis 
HM-335 (VRE) 
















TX0133a04 Texas, USA 2006 
Blood of diabetic patient with 
endocarditis 
Ampicillin and ciprofloxacin 
E. faecium 
HM-959 
513 - - - 





Table 3.2 Continued. 
E. faecium 
NR-28979 (VRE) 
E1162 France 1997 Blood Ampicillin and vancomycin 
E. faecium 
ATCC 700221 (VRE) 






































































Gentamicin and vancomycin 
1
USA = United States of America 
2
VRE = vancomycin-resistant enterococci  
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Table 3.3 Minimum inhibitory concentration (MIC50) (in µg/mL) and minimum bactericidal 
concentration (MBC50) of thiazole compounds 1-3, vancomycin, and linezolid against 50% of 






























































































Figure 3.2 Time-kill analysis of thiazole compounds 1, 2, 3, and linezolid (all tested at 4 × MIC) 
over a 24 hour incubation period at 37 C against A) vancomycin-resistant Enterococcus faecium 
ATCC 700221 and B) vancomycin-resistant Enterococcus faecalis HM-201. DMSO served as a 
negative control. The error bars represent standard deviation values obtained from triplicate 





Figure 3.3 Compound 1 inhibits cell wall biosynthesis in E. coli ΔtolC.  (A, B, F, G) Untreated 
cells. (C, D, H, I) Cells treated with compound 1 for either 30 minutes or two hours at 5 × MIC 
(25 µg/mL). (E, J) Cells treated with D-cycloserine at 5 × MIC (125 µg/mL) for 30 minutes. 
Cells (F-J) were treated in the presence of 0.5 M sucrose to facilitate visualization of cell shape 
defects. Cells were stained with FM 4−64 (red), DAPI (blue), and SYTOX Green (green). Scale 




Figure 3.4 Profiles of membrane and cell wall active compounds in B. subtilis grown in LB at 
37°C. (A, F) Untreated B. subtilis cells show no lysis. (B, G) Cells treated with 0.1% Triton-X-
100, a membrane active compound. (C, H) Cells treated with compound 1 at 5 × MIC (12.5 
µg/mL). (D, I) Cells treated with Vancomycin at 5 × MIC (0.78 µg/mL). (E, J) Cells treated with 
D-cycloserine at 1 × MIC (37.5 µg/mL). Both cell wall inhibitors and membrane active 
compounds cause lysis, which is observed by the increase in staining by SYTOX. Cells were 





Figure 3.5 Profiles of membrane and cell wall active compounds in B. subtilis grown in LB in 
the presence of MSM at 37°C. (A, F) Untreated cells show no cell shape defects or lysis. (B, G) 
Cells treated with 0.1% Triton-X-100. (C, H) Cells treated with compound 1 at 5 × MIC (12.5 
µg/mL), show subtle cell shape defects consistent with cell wall inhibition. (D, I) Cells treated 
with vancomycin at 5 × MIC (0.78125 µg/mL). (E, J) Cells treated with D-cycloserine at 1 × 




Figure 3.6 Comparison of cell shape defects in Bacillus subtilis cells treated with compound 1 or 
vancomycin. All cells are grown in LB in the presence of MSM at 37°C and are shown at two 
hours. Both compound 1 and vancomycin lead to slight bending of the cells and bulges, as 




Figure 3.7 Schematic illustration of some key steps in cell wall biosynthesis in many Gram-




Figure 3.8 Detection of final soluble cell wall precursor (UDP-N-acetylmuramyl pentapeptide) 
inside bacterial cytoplasm. HPLC chromatogram of E. faecalis NR-31975 treated with 10 × MIC 
of compound 1 or vancomycin for 30 minutes. After centrifugation, the bacterial pellet was 
boiled for 30 minutes to release contents present in the bacterial cytoplasm. The lysate was 
analyzed using HPLC/MS to determine the accumulation of the final soluble precursor in cell 






Figure 3.9 Dose response curves for enzyme inhibition by 1 and its effects on the PMF. (A) 
UPPP (YubB) inhibition; bacitracin control. (B) UPPS inhibition, bisamidine NSC-50460 
control. (C) PMF collapse in E. coli IMVs, ATP driven PMF, CCCP control. (D) As C but 





Figure 3.10 Structures of proposed targets of compound 1. The UPPS structure is the X-ray 
structure of EcUPPS, PDB 1X06. The membrane protein structures are models for UPPP 
(YubB), YubA, and YubD. Compound 1 inhibits UPPS and UPPP at low μM levels and 
collapses the PMF (in EcIMVs), suggested to affect the activity of YubA and/or YubD, putative 
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CHAPTER 4: CHAIN LENGTH REGULATION MECHANISM OF CIS-PRENYL 
TRANSFERASES  
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4.2 Introduction 
Undecaprenyl pyrophosphate synthase (UPPS) is a representative enzyme in cis-prenyl 
transferase family which catalyzes the head-to-tail condensation and generates linear polyprenyl 
pyrophosphates in cis form[1] [2], Scheme 1.1 and Scheme 4.1. UPPS catalyzes the condensation 
of farnesyl pyrophosphate (FPP) and 8 molecules of isopentenyl pyrophosphate (IPP), and 
produced cis-Undecaprenyl pyrophosphate (UPP)[3], Scheme 4.1. (C55)-UPP is then 
dephosphorylated to undecaprenyl (mono) phosphate (UP) by undecaprenyl pyrophosphate 
phosphatase (UPPP), followed by the conversion to Lipid I, Lipid II and the formation of 
peptidoglycan (Figure 3.7).[4] Specifically, UP serves as the lipid carrier for the assembly of 
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glycoconjugates.[4] [5] The biosynthesis of bacterial cell wall (peptidoglycan) is essential to 
bacteria and the enzymes involved in the synthesis are important targets for antibiotics 
development.[6] [7]  
Monomeric crystal structures of E. coli UPPS and substrate-bound structures are shown 
in Figure 4.1 (PDB 1X08, 1X09[8]) The highly conserved hydrophobic channel, in cis-prenyl 
transferases, is composed of two 𝛼 helices (𝛼2 and 𝛼3) and four 𝛽-strands (Figure 4.1). The 
substrate binding sites are on top of the hydrophobic tunnel (in view of Figure 4.1B) and both 
IPP and S-thiolo FPP analog FSPP are coordinated by Mg2+ via electrostatic interaction.[8] The 
hydrocarbon chains of intermediates and products are elongated in the hydrophobic channel.[8] [9] 
After the successive condensation reactions (Scheme 4.1), the polyprenyl pyrophosphate product 
reaches its ultimate length (C55) and it was hypothesized that C55-PP pushes away the entrance 
site, drives the relaxation of the hydrophobic tunnel (open conformation), then releases C55-PP 
product and starts a new catalysis cycle.[9]   
The regulation of product chain length in EcUPPS was found to adopt a molecular ruler 
mechanism.[9] Based on the site-directed mutagenesis studies, some residues in the hydrophobic 
channel determines the product chain lengths.[9] The key residues in EcUPPS include Ala-69, 
located in the approximately middle of the hydrophobic tunnel, that is required for rapid 
elongation and the bulky residue Leu137 on the “floor” of the hydrophobic channel, which limits 
the length of the ultimate product (C55).[9] 
The next important question is whether any other region of homodimeric EcUPPS 
regulates or controls the product chain length. C-terminus of each chain locates on the interface 
of two monomers. The C-terminus of one monomer is above, in close proximity to, the active 
sites (substrate binding sites), Figure 4.2A. UPPS enzymes in different bacteria seem conserved 
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in C-termini regions. Figure 4.2B shows the residues in C-termini of UPPS enzymes from S. 
aureus and E. coli (gram positive and gram negative bacteria), based on the sequence alignment 
using Clustal Omega[10]  and Espript3[11]. In Chapter 4, I discuss the investigation on whether and 
how C-termini of EcUPPS and SaUPPS regulate the consecutive condensation and product chain 
length elongation. 
In bacteria, after product C55-PP is produced by soluble UPPS in the cytosol, this highly 
hydrophobic polyprenyl pyrophosphate may spontaneously and rapidly diffuse into the 
membrane.[4] In vitro, 0.1% Triton X-100 facilitates the C55-PP product release by increasing 
stead-steady Km 190 fold.[12] However, the Triton X-100 in the reaction mixture often lacks good 
homogeneity and accessibility.[13] There are other constraints caused by the detergent micelles or 
liposomes, such as interferences in spectroscopy approaches and enzyme binding site(s).[5] [13] 
Taking the above factors into consideration, we selected the emerging and powerful 
membrane mimetic system, termed nanodisc.[14] [15] A nanodisc is composed of a phospholipid 
bilayer with the hydrophobic region encapsulated by two amphipathic belt proteins, membrane 
scaffold protein (MSP).[16] The MSP protein is derived from apolipoprotein A1 (apoA1), which 
is the major component of high-density lipoprotein in blood plasma.[14] [17] Nanodisc platform is 
superior in many aspects including but not limited to: 1) Self-assembled nanodisc enabled the 
reconstitution of various types of phospholipids with 8-16nm in diameter; 2) The lipid 
composition, stability and homogeneity are well-controlled; 3) The nanodisc is able to provide 
the target protein ready access to both sides and native-like lipid environment.[13, 16, 18] 
Presumably, the nanodisc platform would serve as a better mimic of the phospholipid membrane, 
compared to detergents, to stimulate the release of C55-PP product. 
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Overall, this work is focused on studying: 1) The regulation mechanism of EcUPPS by a 
motif between monomers, C-terminus; 2) The interactions of UPPS and the membrane lipids in 
MSP-nanodisc, including the role of C-terminus in this process.  
4.3 Material & Methods 
4.3.1 Chemicals 
TLC Silica gel 60 RP-18 (C18) was purchased from EMD Millipore (#115685). All the 
plasmid, DNA kits were obtained from QIAGEN. FXa kit including FXa and Xarrest agarose 
was obtained from Novagen. Ni-NTA column was purchased from Thermo and DEAE 
Sepharose column was from GE Healthcare. Potato acid phosphatase (PAP) and buffer 
ingredients were all purchased from Sigma-Aldrich. E. coli Polar Lipid Extract was purchased 
from Avanti Polar Lipid Inc., extract of E. coli B (ATCC 11303). NTA-Atto 647N fluorescence 
dye was purchased from Sigma-Aldrich. 
4.3.2 Radioactive (14C) End Product Assay 
The enzymatic end product assays of EcUPPS WT and mutants were carried out in the 
reaction mixture of 55μM 14C-IPP, 100μM FPP, 1μM EcUPPS in the reaction mixture of 100mM 
HEPES-KOH, 50mM KCl, 0.5mM MgCl2, 1μM nanodisc or 0.1% Triton X-100. The generated 
polyprenyl pyrophosphate products were hydrolyzed by potato acid phosphatase (PAP). 
Subsequently, polyprenyl alcohols were then extracted by hexane at least two times (all alcohol 
products have the great solubility in hexane), and then spotted on the TLC plate by the 
compatible capillary. Standards (e.g. farnesol) were spotted on each plate to verify the product 
chain lengths. Besides the standards, Rf values were used for verification in all triplicate 
experiments. The TLC autoradiogram was taken on Molecular Dynamics Phosphoimager after 
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overnight exposure on the screen. The quantity of radioactivity was normalized by the numbers 
of [14C] IPP incorporated.  
4.3.3 UPPS Mutation Enzyme Preparation 
QuikChange Lightning kit (Agilent) was used to perform single and multiple site-directed 
mutagenesis. For the truncation (deletion) study, stop codon was introduced. Preparation 
(expression, purification, and verification) of EcUPPS and SaUPPS wild type and mutant 
proteins was carried out as the previous papers.[6, 19] 
4.3.4 Enzyme Kinetics Measurement 
The enzyme kinetics assay was carried out as Part 2.3.1 in this dissertation, a continuous 
measurement using 2-amino-6-mercapto-7-methylpurine (MESG). Other conditions tested are 
50μM IPP, 2μM FPP, 180nM EcUPPS, 0.3 unit of PNP (Sigma-Aldrich), 0.6 unit of Ppase 
(Sigma-Aldrich), 0.1 mg/mL MESG in the reaction mixture at 25℃. Three concentrations of E. 
coli nanodisc (540nM, 180nM, 90nM) were tested in the reaction mixture without Triton X-100. 
All the assays were carried out in at least triplicate. 
4.3.5 Preparation and Characterization of Nanodisc 
MSP1E3D1, a variant of MSP1 with an addition of 3 helix sequences, was used to be 
assembled with E. coli polar lipids, E. coli total lipids and 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) as the previous report[16]. The number of lipids per nanodisc, in amount, 
was set as 240 based on the composition. 240μL 100mM stock was dried overnight in a pear-
shaped flask, followed by the addition of 750μL 100mM cholate in the buffer containing 20mM 
Tris (pH 7.4), 0.1M NaCl and 0.5mM EDTA. After sonication for 30 minutes (clear solution), 
1.16mL 172μM MSP1E3D1 was added to the lipid resuspension and then the mixture was 
incubated in the cold room (4℃) for 20 minutes under gentle shaking. Then 1.6g equilibrated 
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biobeads was introduced to remove the cholate with a 4.5-hour incubation at 4℃. Then the 
solution with the assembled nanodisc was characterized by DEAE-superdex column, followed by 
the collection of nanodisc with high purity. 
4.3.6 MicroScale Thermophoresis (MST) 
The Monolith NT. 115 MST instrument is from NanoTemper Technologies (Germany). 
The fluorescence probe was Atto 647 N-Nitrilotriacetic acid (Ni-NTA Atto647N, Sigma-Aldrich 
#02175), which has great efficiency in binding MSP of the nanodisc (30-minute incubation in the 
dark), and the labeled nanodisc keeps good stability. There’s no interaction between UPPS and 
the fluorescence probe. Constant concentration (300nM) of fluorescently labeled nanodisc (with 
E. coli polar lipids) and a range of concentrations of EcUPPS ligands (0.9 nM – 7.5 𝜇M) were 
mixed in the buffer containing 100mM HEPES-KOH, 50mM KCl, 0.5mM MgCl2. Before turning 
on the laser, the initial fluorescence intensities of samples with different ligand concentrations 
were measured, to determine there’s no ligand-induced fluorescence change. While the 
temperature gradient was applied, the fluorescence intensities were monitored continuously. 
Normalized intensities were calculated by the ratio of intensities at high temperature and initial 
low temperature (Fhot / Fcold). The experiments were conducted in triplicate. Dose-response 
curves were fitted to calculate Kd value with the instrument software (assuming 1:1). 
 
4.4 Results & Discussions 
4.4.1 Regulation of Product Chain Length by C Terminal in UPPS 
To monitor and quantify the polyprenyl pyrophosphate products with various lengths, I 
utilized the radioactive experiments, with 14C-IPP substrate, coupled with reverse-phase thin 
layer chromatography (TLC). With different ratios of substrates FPP and IPP (possible 
conditions in vivo), different lengths of intermediates and full-length products were formed in the 
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presence of triton.[12] TLC approach is used to demonstrate the product profile of the enzymatic 
reactions in a variety of conditions and 14C radioactive method is sensitive enough for the 
quantitation of products. As shown in Figure 4.3A, the products, polyprenyl pyrophosphates, 
were then dephosphorylated and hydrolyzed by potato acid phosphatase (PAP), followed by the 
extraction in hexane. Those alcohols with various chain lengths were then spotted on RP-TLC 
plates. Figure 4.3B shows the product profile of E. coli UPPS (wild type) in the reaction mixture 
of Triton-X100, and the product distribution is consistent with the previous report.[12] 
Since the C-terminus (loop) of one monomer is in close proximity to the active site of 
another monomer (Figure 4.2A), I examined whether the C-termini of UPPS enzymes affect the 
condensations of IPP molecules and control the ultimate chain lengths of products. Considering 
the spatial positions of C-termini (loop) in UPPS enzymes, I truncated the loop residues in the 
rectangle box shown in Figure 4.2B, and prepared mutants EcUPPS ΔC13 and SaUPPS ΔC9. 
The TLC autoradiogram of EcUPPS ΔC13 is shown in Figure 4.3B. The main product of 
EcUPPS ΔC13 mutant is polyprenyl pyrophosphate C30-PP, which are significantly shorter than 
those of the wild type enzyme (Figure 4.3B). Similar lengths of products were also observed in 
SaUPPS ΔC9 mutant (data not shown). Besides, the enzyme kinetic assay also shows very low 
rate of EcUPPS ΔC13 mutant, at least 1,000-fold difference compared to wild type enzyme (data 
not shown). Taken together, both kinetics and end product measurement indicate the C-termini 
of UPPS enzymes play important role(s) in regulating the product chain lengths. 
The next question is how C-terminus in UPPS controls the elongation of the prenyl 
chains and the chain lengths of the ultimate products. It appears to be common that the terminal 
loops in crystal structures do not have very good electron densities, as the last 12 residues in 
EcUPPS C-terminal and last 3 residues in SaUPPS C-terminal (after examining all crystal 
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structures). Figure 4.4 shows the SaUPPS C-terminus (PDB ID 4H8E[6]) in close proximity to 
ligands FPP S-thiolo analog FSPP and IPP, especially the SaUPPS R249 residue in a distance of 
~ 4.0 Å to the phosphate group of FSPP. Presumably, EcUPPS corresponding residue R242 and 
adjacent R241 may be involved in the electrostatic interaction with substrates or important 
residues in substrate binding, according to the sequence alignment of the C-termini (Figure 4.2B) 
Determined by reverse phase-TLC, the longest lengths of radioactively labeled products of 
mutants of EcUPPS R241A and R242A are both C45, which are two isoprene units shorter than 
WT product (Figure 4.4). On the other hand, R242K appears to have very similar product profile 
as the wild type enzyme, which indicates the arginine residue may be the key residue in chain 
length regulation via electrostatic interaction. 
Since the phosphate groups of UPPS substrates and products should interact with the 
polar head groups of phospholipids[4],  it seems possible that C-terminus would participate in the 
interaction with membrane lipids. 
4.4.2 MSP-Nanodisc Containing E. coli Polar Lipids and its Advantages in Elucidating 
UPPS Mechanism 
Due to the limitations of triton detergent, we proposed a potentially better 
membrane mimetic system, nanodisc[16], to characterize UPPS enzymatic activity with 
biochemical and biophysical approaches, especially the interactions between UPPS 
phospholipids. Two amphipathic helices of membrane scaffold protein (MSP)[16], specifically 
MSP1E3D1, were wrapped around the E. coli polar lipids (67% PE, 23.2% PG, 9.8% CA), and 




As shown in Figure 4.3C (TLC end product assay), MSP-nanodisc (E. coli polar lipids) 
facilitates the dominant production of full-length products in wild type EcUPPS enzymatic 
reaction, which is superior to Triton X-100 in the same condition (Figure 4.3B). Three ratios of 
nanodisc and EcUPPS (3:1, 1:1, 1:2) were measured and the lengths and quantities of the 
products were found to be the same. Enzyme kinetics assays also showed that reaction rates in 
MSP-nanodisc (E. coli polar lipids) are at least 10-fold higher than the rates in 0.1% Triton. 
MSP-nanodiscs with other lipid compositions were also prepared and tested, which are 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and E. coli total lipid extract. These two 
types of nanodisc outperform the Triton in enzyme end product and kinetics assays, but not as 
superior as nanodisc with E. coli polar lipids. 18% (wt %) unknown and unidentified 
component(s) in E. coli total lipid extract are likely to disturb the enzyme functions. Nanodiscs, 
especially those with E. coli polar lipids, indeed provide an ideal, native-like platform to 
characterize the chain length regulation and product release to membrane phospholipids.  
Then the nanodisc, with E. coli polar lipids, was utilized to characterize the function of 
EcUPPS C-terminal mutant, EcUPPS ΔC13. Longest product lengths of EcUPPS ΔC13 mutant 
is C30-PP, same product distribution as the products in Triton (Figure 4.3B), further indicating 
the role of C-terminal in chain length regulation. Even with the ideal lipid platform, the full 
length product cannot be synthesized without the C-terminal.   
4.4.3 Characterizing Interactions between UPPS and Nanodisc Platform 
To further study the interaction between UPPS WT and phospholipids in MSP-nanodisc, 
microscale thermophoresis (MST) was used to measure binding affinity (Kd) of target proteins 
and lipids. The advantages of MST include high accuracy, sensitivity, and almost simultaneous 
measurement of different ligand concentrations. NTA-Atto 647N was applied for the 
94 
 
fluorescence detection of His-tagged protein, MSP in the nanodisc (E. coli polar lipids). EcUPPS 
without His-tag was unlabeled and unaffected in the presence of NTA-Atto probe. Figure 4.5 
shows the dose-response curve of MST affinity assay and Kd is ~1.3 𝜇M, which firstly showing 
the interaction between EcUPPS and E. coli polar lipids experimentally, which is critical for the 
cis-(C55)-UPP product release. 
4.5 Conclusions & Future Work 
UPPS is an important drug target in antibiotics development due to its absence in human 
and essential role in many bacteria.[20] UPPS synthesizes the precursor of lipid carrier, (C55) – 
UPP, in cytosol, which is essential in peptidoglycan biosynthesis.[4] This work determines that 
the motif C-terminal, in the monomer interface, regulates the product chain lengths and is critical 
to generate the full length product. Site-directed mutagenesis studies show that Arg residue in C-
terminal is important in the substrate binding, and it is possible that C-terminal is involved in the 
binding of intermediate products, which requires further investigations. 
Full length (C55)-UPP product is released to membrane lipids in vivo after the interaction 
between enzyme-product complex and phospholipids.[4] This work firstly proposed the native-
like membrane nanodisc system to characterize membrane-associated enzyme UPPS. MSP-
nanodisc with E. coli polar lipids is demonstrated to be an optimal platform for functional study. 
It presents much faster kinetics, and the formation of full-length products (C55)-UPP, which are 
the advantages over Triton. Microscale thermophoresis (MST) is used to identify the Kd between 
EcUPPS and the nanodisc is estimated to be ~1.3 𝜇M. The ongoing investigations and attempts 
include further characterizing the interaction utilizing surface plasmon resonance and isothermal 
titration calorimetry. Furthermore, MST would be also utilized to measure the binding affinity of 
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EcUPPS C-terminus mutant and the nanodisc, to test whether C-terminus is involved in the 
product release process. 
Intriguingly, the nanodisc experimental platform can be potentially applied to other 
relevant enzymes, such as the downstream enzyme undecaprenyl pyrophosphate phosphatase 
(UPPP) that dephosphorylated (C55)-UPP. Thus, the future endeavor would include the assembly 
of EcUPPP into the nanodisc (E. coli polar lipids) and characterization of membrane protein 
EcUPPP in the new nanodisc system. It would be more interesting to explore the sequential steps 





4.6 Scheme and Figures 
 





Figure 4.1 Two views of X-ray crystal structures of undecaprenyl pyrophosphate synthase 
(UPPS) from E. coli (PDB 1X08, 1X09), similar to Figure 1.2. A) Two monomers are shown as 
green and orange cartoons, respectively. S-thiolo FPP analog FSPP is shown in sphere. B) One 
monomer is shown in cartoon while another monomer is shown in surface (back). Two ligands, 




Figure 4.2 A) Superimposition of SaUPPS (PDB ID 4H8E) and EcUPPS (PDB ID 1X08, 1X09) 
that are highly conserved. Two monomers of SaUPPS are shown as a green cartoon and a green 
surface, respectively. Yellow and blue sticks are ligands FSPP and IPP. C terminal of SaUPPS 














Figure 4.3 Radioactive end product assay. A) Radioactive (14C) UPPS reactions. B) RP-TLC 
autoradiogram of polyprenyl alcohols corresponding to products synthesized by enzymes 
EcUPPS wild type and ΔC13. C) RP-TLC autoradiogram of polyprenyl alcohols corresponding 







Figure 4.4 A close view of UPPS substrate binding site, as Figure 4.2. SaUPPS (PDB ID 4H8E) 
and EcUPPS (PDB ID 1X08, 1X09) are highly conserved and superimposed. Approximate 
spatial position of EcUPPS R242 is indicated with the purple ligand (SaUPPS corresponding 
residue R249). The table shows a summary of longest polyprenyl pyrophosphate products of 




















Figure 4.5 One representative dose-response curve of MST affinity assay. FNorm, in Y-axis, 
stands for the normalized fluorescence intensity (Fhot/Fcold). X-axis shows the molar 
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CHAPTER 5: STRUCTURE AND FUNCTION OF A HEAD-TO-MIDDLE PRENYL 
TRANSFERASE: LAVANDULYL DIPHOSPHATE SYNTHASE (LPPS)  
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5.2 Introduction 
First head-to-middle prenyl transferase, lavandulyl diphosphate synthase (LPPS), was 
reported in 2013 and it catalyzes two molecules of dimethylallyl diphosphate (DMAPP) and 
forms a branched product lavandulyl pyrophosphate (LPP) in a head-to-middle manner (Scheme 
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5.1).[1] LPP is the precursor of the commercially important fragrances (R)-lavandulol and (R)-
lavandulyl acetate. No structure of any head-to-middle prenyl transferase was reported. 
Based on a BLAST (basic local alignment search tool)[2] search of all reported 
genomes, LPPS has closest homology (ca. 47% identity over 234 residues) to (plant) 
dehydrodolichyl diphosphate synthases, but none of these structures have been reported. 
Compared with bacterial genomes, LPPS has close homology to undecaprenyl diphosphate 
synthases, UPPS, (ca. 42% identity) for a catalytic “core” of 230 LPPS residues. The structures 
several of UPPS were reported.[3] [4] However, it has also been shown that LPP can be made by 
achimeric terpenoid synthase with the conventional “FPPS-like” fold (PDB ID code 4KK2).[5] 
Here, we sought to determine the structure of LPPS from Lavandula x intermedia; to determine 
how ligands bind; and to further propose a structure-based mechanism of action of monoterpene 
synthase LPPS. 
5.3 Material & Methods  
5.3.1 Enzyme Preparation  
The gene encoding full-length LPPS  (Lavandula x intermedia lavandulyl pyrophosphate 
synthase GenBank accession number: AGH33890.1) was chemically synthesized by GENE ray 
Biotech Co. and ligated into the vector pET46Ek/LIC. Using the full-length LPPS as a template, 
the genes encoding ΔN55-LPPS was amplified by PCR and ligated into the same vector. The 
recombinant plasmids were verified by sequencing.  
Site-directed mutagenesis was conducted by the kit called QuickChange (Agilent 
Technologies, Santa Clara, CA, USA) and plasmids containing the genes encoding protein 
mutants were verified by sequencing. All used primers can be found in Cloning Section in 
Supporting Information of the paper.[6] 
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The plasmids were transformed into E. coli BL21 (DE3) cells using heat shock, and 
expression was induced by 0.3 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 16 °C for 
24 hours. Cells were harvested by centrifugation at 5,000 g for 10 minutes and resuspended in 
the lysis buffer containing 25 mM Tris-Cl (pH 7.5), 150 mM NaCl and 20 mM imidazole 
followed by disruption with a French Press. Cell debris was removed by centrifugation at 17,000 
g for 1 hour. To purify the proteins, the supernatants were then applied to a Ni-NTA column 
FPLC system (GE Healthcare). The target proteins eluted at ~100 mM imidazole when using a 
20-250 mM imidazole gradient. Proteins were then dialyzed against buffer containing 25 mM 
Tris-HCl (pH 7.5) and loaded onto a DEAE Sepharose column (size exclusion column). Target 
proteins were eluted at ~200 mM NaCl when using a 0-500 mM NaCl gradient. The purified 
proteins were passed through a Superdex 200 column and further concentrated to 21 mg/mL in 
the storage buffer containing 25 mM Tris-Cl (pH 7.5) and 150 mM NaCl. Protein purity was 
measured by SDS-PAGE analysis.  
5.3.2 Crystallization and Data Collection. 
LPPS crystals were initially obtained by using a Crystal Screen Cryo kit (Hampton 
Research) (#39: 0.085 M HEPES-Na, pH 7.5, 1.7% v/v polyethylene glycol 400, 1.7 M 
ammonium sulfate, 15 % v/v glycerol) using the sitting-drop vapor diffusion method. 1 μL 
protein (3.3 mg/mL) was mixed with 1 μL of reservoir solution in 48-well Cryschem Plates, and 
equilibrated against 100 μL of the reservoir at 25°C. Within 2-3 days, crystals reached a size 
suitable for X-ray diffraction. Crystals with DMASPP and ISPP were obtained with by soaking 
the apo-LPPS crystals in mother liquor containing 10 mM ligand for 1 hour, prior to data 
collection. Then Crystals were mounted in a cryo-loop and flash-cooled by liquid nitrogen for X-
ray data collection. Data sets were collected at beamlines BL15A1, BL13B1, and BL13C1 of the 
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National Synchrotron Radiation Research Center (NSRRC, Hsinchu, Taiwan). Details of 
structure determination can be found in Supporting Information of the paper.[6] 
5.3.3 Enzymatic Activity Assay. 
Enzymatic assays were conducted in 200 μL reaction mixtures containing 600 μM 
DMAPP substrate, 0.2 mg wild type LPPS and mutants, 50 mM Tris-HCl (pH 8.0), 5% glycerol, 
1 mM DTT, 1 mM MnCl2[1]. The LPPS reactions were carried out for 2h at 30 °C. To hydrolyze 
the isoprenoid diphosphate products to the alcohols, 40 units of calf intestinal alkaline 
phosphatase (CIP, New England Biolabs) in 40 μL of 500 mM glycine (pH 10.5), 5 mM ZnCl2 
followed by the incubation at 1h at 37 °C[7]. 550 μL of saturated NaCl was then added and the 
mixtures were extracted three times with hexane. The extracts were dried under a stream of 
nitrogen and 50 μL fresh hexane was added. 1 μL of each extract was analyzed by gas 
chromatography-mass spectrometry (GC-MS) on a 30 m   0.25 mm ✕ 0.25 μm DB-5MS 
column (Agilent Technologies) with oven temperature starting at 40 °C for 5 min isothermal, 
ramping to 125 °C by 4 °C min-1, followed by another temperature increase to 250 °C by 30 °C 
min-1, with a final hold time of 3 min. Electron ionization mass spectrometry EI-MS was coupled 
to GC. The mass spectra and retention times of eluted peaks were compared those of the 
authentic lavandulol (Alkemist Labs), geraniol (Sigma-Aldrich) and chrysanthemyl alcohol 
(Sigma-Aldrich). Products of enzymatic assays were verified as lavandulol and further quantified 
by the integration of the peak areas. 
5.4 Results & Discussions 
5.4.1 Apo Crystal Structure 
We first attempted to crystallize the full-length construct of LPPS (316 residues) 
containing the putative catalytic domain (261 residues) and the chloroplast-targeting[8] N-
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terminus (55 residues). We were not successful in obtaining the soluble protein, due perhaps to 
the presence of the lipid (membrane) targeting domain. We thus expressed truncated proteins 
with 55 N-terminal residues deleted. The Δ 55 protein was successfully expressed and 
crystallized. Crystals were diffracted to 1.87Å resolution and full crystallographic data 
acquisition and structure refinement details are given in Table 5.1. LPPS crystallized in the 
orthorhombic space group C2221 and the structure of the dimeric apo-protein (PDB ID code 
5HC6) is shown in Figure 5.1A. 
5.4.2 High Structural Similarity to Cis-Prenyl Transferases  
Using the PDBeFold server[9], we find that the (plant) LPPS has high structural similarity 
to the bacterial protein UPPS from both Staphylococcus aureus (PDB ID code 4U82, a 1.16 Å 
C rmsd over 232 aligned residues) and E. coli (PDB ID code 1XO6, a 1.11 Å C rmsd over 
225 aligned residues).  A structural superimposition of apo-LPPS with EcUPPS is shown in 
Figure 5.1B in which the two ligand binding sites in UPPS—the allylic S1 site into which FPP 
binds and the IPP site S2—are indicated. Analogous sites are present in the LPPS structure and 
are occupied by sulfate (Figure 5.2). LPPS structure is also very similar to those of the cis-FPP 
and cis-decaprenyl diphosphate synthases from Mycobacterium tuberculosis (Figure 5.1C, D). 
These structural similarities are of interest since the mechanism of action of UPPS is well 
understood[10]. In UPPS, the allylic species (initially, FPP) binds to the allylic site S1 with both 
phosphates in its diphosphate group bound to a single Mg2+ which in turn is coordinated to a 
highly conserved Asp (D26 in E. coli UPPS), which based on sequence and structural alignments 
(Figure 5.3) is also present in LPPS (D76, due to the presence of the N-terminal plastid-targeting 
sequence), as well as in the homologous Mycobacterium tuberculosis cis-farnesyl and cis-
decaprenyl diphosphate synthases (Figures 5.3). In UPPS, there is also a second, homoallylic 
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binding site, S2, that houses the IPP used in chain elongation. Mechanistically, in UPPS the 
allylic diphosphate in S1 is attacked by the IPP double bond (in S2) in a concerted (that is, not 
sequential) manner, resulting in diphosphate loss and chain elongation. Logically, then, it would 
follow that in LPPS, one DMAPP should bind to the S1 allylic site with multiple interactions 
between its diphosphate and Mg2+, facilitating pyrophosphate removal, while the second 
DMAPP would bind to S2 site. However, UPPS does not condense DMAPP to LPP, and LPPS 
does not condense DMAPP and IPP to longer chain species, so there must be important 
differences in active site structure/ligand binding between the two proteins. We thus next sought 
ligand-bound structures. 
5.4.3 Ligand-Bound Crystal Structures 
We soaked LPPS crystals with S-thiolo-dimethylallyl diphosphate (DMASPP, Scheme 
5.1), and for comparison, S-thiolo-isopentenyldiphosphate (ISPP, Scheme 5.1). Full data 
acquisition and structure refinement details for the DMASPP (PDB ID code 5HC8) and ISPP 
(PDB ID code 5HC7) complex structures are given in Table 5.1. The complex structures are very 
similar to the apo structure (PDB ID code 5HC6) with ~0.1 Å C rmsd values, indicating that 
protein folding is not significantly altered on ligand binding. There were, however, some 
surprises. With DMASPP, the ligand electron density in the S2 site is well defined, Figure 5.4A, 
and there is clearly a bond between one phosphate and Mg2+ (which is also coordinated to D76 
and two water molecules). However, equally clearly, there is a break in the electron density for 
the species in the allylic site, S1, as can be seen in Figure 5.4A. There is a well-defined 
diphosphate (presumably actually a thiodiphosphate) group in S1 bound via both phosphates to 
Mg2+, together with a planar C5 species below the diphosphate and with no connecting electron 
density. Only two sulfates can be modeled into the pyrophosphate binding site in apo LPPS 
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crystals prior to soaking with DMASPP (Figure 5.2) so it appears that the DMASPP in S1 is 
unusually reactive, ionizing to form PPi and the dimethylallyl carbocation which then loses a 
proton to form the planar C5 species, isoprene. With ISPP, Figure 5.4B, the electron density 
results show, once again, a well-defined ISPP ligand bound in the S2 site but only a PPi (bound 
to Mg2+) in S1, together with a small additional density perhaps due to an H2O (Figure 
5.4B). This result was even more surprising than the DMASPP result because the homoallylic 
species ISPP is expected to be less reactive chemically than the allylic DMASPP.  
We thus determined a second ISPP structure using a commercial sample of ISPP and 
obtained the same results (Figure 5.5). It thus appears that the S1 site in LPPS catalyzes 
diphosphate ionization with both DMASPP and ISPP, facilitating perhaps, the “head-to-middle” 
condensation reaction with DMAPP. There was no organic fragment observed with ISPP (on 
SPPi loss), suggesting formation of a polar (isopentenyl alcohol) product that would not bind 
tightly to the hydrophobic S1 site. Why then might DMASPP and ISPP be cleaved, in S1? And 
how might this relate to catalytic activity?  
5.4.4 Enzymatic Activities of Wild Type and Mutants, Structure-Activity Relationship 
On inspection of the amino-acid sequences (Figure 5.3), as well as the LPPS/UPPS X-ray 
structures (Figure 5.6), we see that there is one major difference (in the S1 active site region) 
between LPPS and the other cis-prenyl transferases. Specifically, LPPS contains an active site 
His (His78), but in all of the other proteins the corresponding residue is a (neutral) asparagine. 
The other, basic, active site residues in LPPS and the structurally homologous cis-prenyl 
transferases are all located in similar spatial positions in both the S1 and S2 sites (Figure 5.6), 
suggesting that His78 might be important in catalyzing the LPPS reaction, by facilitating PPi 
loss. To test this hypothesis, we produced the H78N LPPS mutant (since Asn is present in 
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UPPS). There was no activity lavandulyl diphosphate formation found (Figure 5.7). We also 
produced Y139F and W100V mutants, based on the UPPS structures. Y139F had 62% the 
activity of WT while W100V had 15% activity, so these mutations do have effects on 
folding/activity, but clearly only H78 is essential for catalysis.  
5.4.5 Proposed Structure-Based Mechanism of Action 
The X-ray crystallographic, sequence homology and mutagenesis results thus lead to the 
LPPS mechanism of action shown in Figure 5.8. Figure 5.8A shows a view of the LPPS active 
site region in which, for clarity in explaining the catalytic mechanism, we have connected the 
PPi and C5 fragments in the DMASPP structure to model a DMAPP. A ChemDraw version of 
this substrate-bound model is shown in Figure 5.8B and the product-bound model is shown in 
Figure 5.8C. The proposed mechanism is as follows. First, loss of PPi from the DMAPP in S1 is 
facilitated by the presence of the basic residue His78, Figure 5.8B, since there are 2.8 Å and 4.1 
Å interactions between the H78N1 and (P1)O1,(P1)O2, and a 2.7 Å interaction between 
R127N and (P1)O2. The double bond in the DMAPP in S2 then attacks the carbocation in S1 
forming the “lavandulyl carbocation”[1]—although a concerted reaction cannot be ruled out. 
There are no basic residues near the DMASPP in S2 to affect the required proton abstraction to 
form LPP (Figure 5.9) but one oxygen in the proximal phosphate is only 3 Å from one of the 
DMAPP methyl protons (in the DMASPP structure), suggesting this phosphate acts as the base-
just as proposed for the proximal DMAPP phosphate in the isoprene synthase reaction[11]. The 
DMASPP (S1; C1) to DMASPP (S2; C2) distance is long (~5.4 Å)-but this is actually the same 
distance as found between the two FPP (FSPP) molecules in dehydrosqualene synthase[12]. which 
condense to form PSPP—so such large ligand movements do have precedent in prenyl synthases. 
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In addition, based on this structural model, the product is (R)-lavandulyl diphosphate, as found 
experimentally. 
5.5 Conclusions & Summary 
In summary: we obtained the first structure of a “head-to-middle” isoprene synthase, 
lavandulyl diphosphate synthase, and propose a detailed structure-based mechanism of action. 
The structure of this plant enzyme is remarkably similar to that found in many bacterial cis-
prenyl diphosphate synthases. The S-thiolo analogs of DMAPP and IPP bound to the “S2” site 
occupied by IPP in the conventional cis-prenyl transferases, but in both cases, the S1 site 
contained a diphosphate (bound to Mg2+) together with, in the case of DMASPP, a planar C5 
species. The most obvious structural/sequence difference between LPPS and the other cis-prenyl 
transferases in the active site region is the presence of an active site His (H78) in LPPS, which is 
Asn in the other proteins. An H78N mutant did not catalyze LPP production, consistent with a 
key role for this His in catalysis. There were no basic residues close to the S2 DMAPP methyl 
groups, suggesting that the proximal phosphate group acts as the base need to deprotonate the 
‘lavandulyl carbocation' intermediate—basically the same role as the DMAPP (di)phosphate in 
isoprene synthase. Overall, the results are of broad general interest since we have determined the 
first structure and structure-based mechanism of action of the irregular terpene synthase, 
lavandulyl diphosphate synthase, involved in the formation of the commercially important 




5.6 Scheme, Table and Figures 
Scheme 5.1 Scheme of LPPS reaction and structures of some isoprenoid compounds discussed in 





Table 5.1 Data collection and refinement statistics for LPPS crystals. 
 
 Apo LPPS/ISPP LPPS/DMASPP 
PDB code 5HC6 5HC7 5HC8 
Data co1lection BL13B1 BL13C1 BL15A1 
Space group C2221 C2221 C2221 
Unit-cell    
a [Å] 54.357 54.392 54.211 
b [Å] 142.085 141.606 140.235 
c [Å]  78.666 78.918 78.702 






25-2.05 (2.12-2.05) 25-1.87 (1.94-1.87) 
Unique reflections 16659 (1569) 19241 (1783) 25038 (2407) 
Redundancy 3.5 (3.4) 3.5 (3.3) 4.5 (4.2) 
Completeness [%] 98.0 (93.5) 98.9 (93.4) 99 (96.9) 
Average I/σ(I) 22.37 (2.44) 24.10 (2.49) 26.06 (3.78) 
R merge[a] [%] 5.4 (41.8) 5.6 (42.0) 3.9 (34.9) 
    
Refinement    
No. of reflections 15763 (1047) 18346 (1216) 23751 (1704) 
Rwork[a] (95 % of 
data) 
0.179 (0.300) 0.175 (0.287) 0.177 (0.283) 
Rfree[a] (5 % of data) 0.234 (0.348) 0.221 (0.263) 0.219 (0.344) 
r.m.s.d. bonds [Å] 0.016 0.022 0.021 
r.m.s.d. angles [º] 1.971 2.069 2.049 
Dihedral angles    
Most favored [%] 93.5 95.6 96.2 
Allowed [%] 5.3 3.9 3.0 
Disallowed  [%] 0.9 0.4 0.9 
No. of non-H atoms / 
average B [Å2 ]  
   
Protein 1852/49.71 1852/44.25 1903/37.89 
Water 50/52.92 80/48.95 133/45.64 
Ion 15/68.44 1/5.65 6/49.62 
Ligand  23/55.75 28/34.53 
 
Values in parentheses are for the highest resolution shell. 
a Rmerge = ∑hkl∑i|Ii(hkl)-<I(hkl)>| / ∑hkl∑iIi(hkl). 
114 
 
Figure 5.1 Structure of Lavandula x intermedia LPPS and comparisons with the structures of 
three cis-prenyltransferases. A) Structure of the dimeric protein in complex with sulfate (PDB ID 
code 5HC6). B) Structural superimposition of LPPS (green; PDB ID code 5HC6) with EcUPPS 
in complex with IPP and FPP (yellow; PDB ID codes 1X08 and 1X09). C) As (B) but with 
M. tuberculosis cis-farnesyl diphosphate synthase in complex with FPP, Pi (Rv1086, PDB ID 
code 2VG1, cyan). D) As (B) but with cis-decaprenyl diphosphate synthase in complex with 




Figure 5.2 Electron density maps of the two sulfate ions found in apo-form LPPS (PDB ID code 
5HC6) contoured at 1.0 σ (gray) and 3.0 σ (red). The S1 and S2 sites are indicated. These sulfate 




Figure 5.3 Sequence alignment of L. x intermedia LPPS (LiLPPS) together with several other 
enzymes adopting the cis-prenyltransferase fold. EcUPPS is UPPS from E. coli; SaUPPS is 
UPPS from S. aureus; Rv2361 is cis-decaprenyl diphosphate synthase from M. tuberculosis; 
Rv1086 is cis-farnesyl diphosphate synthase from M. tuberculosis. S1 and S2 site-forming 
residues are denoted as blue and red circles, respectively.  
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Figure 5.4 Electron density maps of bound ligands (stick) and Mg2+ (sphere), contoured at 1.0 σ 





Figure 5.5 Electron density maps of bound ISPP and SPPi (sticks), Mg2+ (blue sphere), and 
waters (red spheres) in LPPS structure in complex with commercial ISPP (Echelon Biosciences), 
contoured at 1.0 σ (gray) and 3.0 σ (red). Note that the structure is essentially identical to that 
obtained with in-house synthesized ISPP, Figure 5.4A. The S and O in the (SPPi) are presumably 




Figure 5.6 Stereoview of the S1 and S2 site-forming residues in LPPS (cyan, PDB ID code 
5HC8, blue letters) and EcUPPS (yellow, PDB ID code 1X08, red letters). A) S1 site. B) S2 site. 
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Figure 5.7 Activity of LPPS for wild-type, H78N, W100V and Y139F LPPS mutants as 





Figure 5.8 Proposed LPPS mechanism of action. A) A view of the LPPS active site. B) 





Figure 5.9 Residues in LPPS (PDB ID code 5HC8) that are within ~5 Å of the methyl groups in 
the S2 DMASPP. There are no amino acid residues that could remove H+ from the lavandulyl 
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CHAPTER 6: HEAD-TO-MIDDLE AND HEAD-TO-TAIL CIS-PRENYL 
TRANSFERASES: STRUCTURE OF ISOSESQUILAVANDULYL DIPHOSPHATE 
SYNTHASE (ILPPS) 
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6.2 Introduction 
More recently, UPPS-like enzymes head-to-middle prenyl transferases have been 
reported to catalyze the attack of the C2–C3 double bonds (Scheme 6.1).[1] [2] [3] For example, the 
double bond of DMAPP (an allylic substrate, Scheme 6.2) in S2 site attached  C1 in a second 
allylic substrate, forming the C10 species lavandulyl diphosphate (LPP, Scheme 6.2). This 
reaction is catalyzed by lavandulyl diphosphate (LPPS) and mechanism of action of LPPS has 
been discussed in Chapter 5. LPPS has very high structural similarity to UPPS.[1]  
As discussed in Chapter 4, UPPS, a cis-prenyl transferase (PT) catalyzes the 
condensation in a head-to-tail manner (Scheme 6.1), and it is composed of both α-helix and β-
sheet structures where the allylic diphosphate (FPP) binds to Mg2+ in S1 site, and the homoallylic 
diphosphate IPP binds to S2 site (Figure 6.1A, PDB ID codes 1X08, 1X09).[4] The UPPS fold is 
also adopted by other proteins, such as tuberculosinyl adenosine synthase,[5] [6] which catalyzes 
the condensation of tuberculosinyl diphosphate (Scheme 6.2) with adenosine to form 
tuberculosinyl adenosine (Scheme 6.2), a virulence factor in Mycobacterium tuberculosis.[7] 
In other recent work, an unusual analog of LPP, “isosesquilavanduly diphosphate (ILPP, 
Scheme 6.2), has been reported and shown to be involved in the biosynthesis of the merochlorin 
class of antibiotics found in Streptomyces sp. Strain CNH-189.[3] [8] The biosynthesis of ILPP 
involves the head-to-middle condensation of DMAPP with GPP (Scheme 6.2), forming the 
branched C15 compound. This reaction is catalyzed by isosesquilavandulyl diphosphate synthase, 
Mcl22 (ILPPS), and here, we were interested in determining the structure of Mcl22; how 
substrates bind, and more specifically, how the protein structure controls the product structure 
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and substrate specificity. The results we find are quite surprising and give unexpected 
perspectives into the catalysis by prenyl transferases. 
6.3 Material & Methods  
6.3.1 Substrate and Enzyme Preparation  
S‐thiolo geranyl diphosphate was purchased from Echelon Biosciences (United States). 
The gene encoding full‐length Mcl22 (Streptomyces sp. CNH189, WP_024888525) was 
chemically synthesized by GENE Ray Biotech Co. (Shanghai, China), amplified by polymerase 
chain reaction with the primers 5'‐GACGACGACAAGATGATGACCAATCTGATGCTG‐3' 
(forward) and 5'‐GAGGAGAAGCCCGGTTATTAAACCGGATACAGACCATA‐3' (reverse), 
and ligated into plasmid pET46Ek/LIC.   
A series of mutants were also prepared: M11H, M11N, Y26H, Y26F, M29G, T51W, 
T51Y, S54A, N57A and Y58A. M11 of Mcl22 corresponds to H78 of LPPS and N28 of 
EcUPPS, and in previous work[1] we showed that the H78N mutant of LPPS was inactive. Thus, 
M11H and M11N mutants of Mcl22 were constructed and tested for activity. Y26 is in close 
proximity to the pyrophosphate of GPP in Mcl22 S1 site and the corresponding residue in the 
other two enzymes is His. Thus, Y26H of ILPPS was investigated. M29 in Mcl22 corresponds to 
Gly in both LPPS and EcUPPS, which might form a blockade of the central hydrophobic tunnel 
in EcUPPS. Thus, M29G mutant of Mcl22 was constructed and tested for activity. The residues 
corresponding to T51 in LPPS and EcUPPS are Trp and Tyr respectively, which provide 
stacking forces that can stabilize the C5 moiety of the substrates in the S2 site. T51 of Mcl22 
lacks the ability to support stacking forces so it was mutated to Trp and Tyr and the activities of 
the mutants were tested. S54 and N57 are conserved in all three proteins and we hypothesized a 
role in H+ removal, so both S54A and N57A mutants were prepared and investigated. Y58 of 
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Mcl22 is located next to N57 and the hydroxyl group of Y58 is close to that of S54 thus the 
mutant Y58A of Mcl22 was prepared. The QuikChange site-directed mutagenesis kit (Agilent, 
United States) was used to prepare all the mutants. All used primers can be found in Supporting 
Information of the paper.[9] 
The wild-type and mutant plasmids were transformed individually into E. coli BL21 
(DE3) cells. Protein expression was induced by 0.2 mM isopropyl β‐D‐1‐thiogalactopyranoside 
(IPTG) at 16°C for 24 hours. Cells were harvested by centrifugation at 5,000 g for 15 minutes 
and then resuspended in a buffer containing 25 mM Tris•HCl (pH 7.5), 150 mM NaCl and 20 
mM imidazole. Cells were disrupted with a French Press and centrifuged at 17,000 g for 1 
hour. The supernatant was then applied to a Ni‐NTA column on an FPLC system (GE 
Healthcare) at 4 °C, using a 20‐500 mM gradient, and the target protein was eluted at ~100 mM. 
The protein was dialyzed against 25 mM Tris‐Cl (pH 7.5) and loaded onto a DEAE Sepharose 
column. The target protein was eluted at ~200 mM NaCl when using a 0‐500 mM 
gradient. Protein purity was verified by SDS‐PAGE analysis. The wild‐type protein was 
concentrated to ~10 mg/mL in a buffer containing 25 mM Tris‐Cl (pH 7.5) and 150 mM NaCl, 
for crystallization. 
6.3.2 Crystallization and Data Collection  
Mcl22 crystals were initially obtained by using Hampton Research Screening Kits using 
the sitting‐drop vapor diffusion method in which 1 µL protein was mixed with 1 µL reservoir 
solution in 48‐well Cryschem Plates and equilibrated against 100 µL of the reservoir at 25°C. 
Native crystals were found in wells of Index II #46 (I46): 0.2 M Na3C6H5O7, 20% v/v 
polyethylene glycol (PEG) 3350, and Wizard III #47 (W47): 0.2 M (NH4)2SO4, 0.1 M MES (pH 
6.5), 30% PEG 5000 MME. The crystals reached a size suitable for X‐ray diffraction in one 
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month. Native data sets were collected using the W47 crystals. The DMAPP and GPP complexes 
with Mcl22 were each obtained by soaking W47 crystals in 5 mM MgCl2, 0.2 M (NH4)2SO4, 0.1 
M MES (pH 6.5), 30% PEG 5000 MME and 10 mM of the ligand for 16 hours, prior to data 
collection. The GSPP+DMAPP complex was obtained by soaking the I46 crystal in 5 mM 
MgCl2, 0.2 M Na3C6H5O7, 24% v/v PEG 3350, 10% (v/v) glycerol and 10 mM of both ligands 
for 16 hours. Each crystal was mounted in a cryo‐loop and flash‐cooled with liquid nitrogen. All 
data sets were collected at beam line BL5A and BL15A1 of the National Synchrotron Radiation 
Research Center (NSRRC, Hsinchu, Taiwan). Details of structure determination can be found in 
Supporting Information of the paper.[9] 
6.3.3  Enzymatic Activity Assay Measurement  
MESG assay, discussed in Section 2.3.1 (Chapter 2), was utilized to monitor the 
enzymatic activity of wild-type and mutant Mcl22 enzymes. The 360nM absorbance was 
monitored continuously for the 200 µL reaction mixtures containing 140 mM MESG, 0.004 
mg/ml purine nucleoside phosphorylase, and inorganic pyrophosphatase, 50 mM GPP, and 50 
mM DMAPP, in the buffer of 50 mM Tris‐HCl (pH 7.5), 0.1 mM sodium azide and 1 mM 
MgCl2. 
End product formation assay was performed in 50 μL reaction mixtures containing 100 
μM DMAPP, 100 μM GPP, 1 μM Mcl22 at room temperature for 2 hours in 20 mM HEPES‐
NaOH (pH 7.8), 10% v/v glycerol, 150 mM NaCl and 5 mM MgCl2. The mixtures were 
analyzed by reverse‐phase HPLC‐mass spectrometry (Agilent 1100 LC/MSD Trap XCT Plus) on 
a 150 mm × 4.6 mm, 5 μm C8 column (Agilent ZORBAX Eclipse XDB) with 80% (v/v) water 
(buffered with 25 mM NH4HCO3, 0.1% trimethylamine TEA, pH 8.0) and 20% (v/v) acetonitrile 
(with 0.2% TEA) at a flow rate of 350 μL min‐1. Chromatographic peaks were analyzed by using 
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extracted ion chromatograms together with retention times of GPP ([M‐H]- 313.1) and FPP ([M‐
H]- 381.1) as standards. The same approach was used to determine the relative activity (%) of the 
Mcl22 mutants. Above activity experiments were carried out in triplicates. 
6.4 Results & Discussions 
6.4.1 Apo and Ligand-Bound Crystal Structures 
We crystallized the apo-protein and solved its structure (PDB ID Code 5XK3) using the 
M. tuberculosis cis-FPPS structure (Rv-1086; PDB ID code 2VFW) as a template. We also 
solved DMAPP (PDB ID code 5XK7); GPP (PDB ID code 5XK8) and DMAPP+S-thiolo-
geranyl diphosphate (GSPP; PDB ID Code 5XK9) liganded structures to enable mechanistic 
proposals (Figure 6.1). Data acquisition and structure refinement details are given in Table 6.1 
and Table 6.2. Figure 6.2 shows a stereo-view of the apo-structure (PDB ID code 5XK3), which 
has the same “butterfly”-shaped dimer structure seen in other cis-prenyl 
transferases. Superimposed Mcl22 (PDB ID code 5XK3) and E. coli UPPS (PDB ID code 1X08) 
monomer structures are shown in Figure 6.1A. In the GPP structure (PDB ID code 5XK8), 
Figure 6.1B, the diphosphate moiety binds in the allylic site S1 and interacts with Mg2+. In the 
DMAPP complex (PDB ID code 5XK7), DMAPP binds in the S2 site while the S1 site is 
occupied by PPi, Figure 6.1C, and both ligands coordinate to Mg2+. In the GSPP + DMAPP 
complex (PDB ID code 5XK9), both GSPP as well as DMAPP bind to Mg2+, Figure 6.1D. What 
are also shown are selected, highly conserved residues (based on a SCORECONS[10] analysis and 
a sequence alignment, Figure 6.3) that are hypothesized or known to be involved in catalysis in 





6.4.2 Unique Substrate Binding Site 
Remarkably, not readily apparent in the structure-views shown in Figure 6.1B-D is the 
fact that the C10 (geranyl) group in GPP/GSPP in the S1 site does not occupy the “canonical” S1 
ligand-binding site seen in, for example, UPPS, cis-UPPS, cis- decaprenyl diphosphate synthase 
(Rv2361) from M. tuberculosis, or tuberculosinol adenosine synthase from M. tuberculosis. 
In the UPPS structure, Figure 6.4A, the C15 FPP substrate is oriented in what we shall call 
an essentially “vertical” position in which the C15 side-chain is oriented along the S1-S4 axis 
seen in UPPS.[4] However, in Mcl22, the geranyl group is oriented in the S1-S3 plane, at ~90° to 
the chain axis seen in other cis-prenyl transferases. As can be seen in Figure 6.4A, this 
orientation can be attributed to a steric effect in Mcl22 since helices 2 and 3 (cyan) are much 
closer to each other than are the corresponding helices in UPPS (green). That is, GPP cannot fit 
into the “normal”, central hydrophobic channel. In the cis-FPPS from M. tuberculosis (Rv1086), 
the same effect is seen in which the Rv1086 𝛼2 and 𝛼3 helices are more distant from each other 
than they are in Mcl22 in both FPP (PDB ID code 2VG1) as well as in citronellyl diphosphate 
(Figure 6.4B; PDB ID code 2VG0) structures.[11] And as expected, the corresponding helices 
(PDB ID code 3WQN) in Rv3378c (tuberculosinyl adenosine synthase) are even more distant 
than in Mcl22, since Rv3378c needs to accommodate the even bulkier C20 isoprenoid, 
tuberculosinyl diphosphate (compound 4 in Scheme 6.2), Figure 6.4C. The canonical 
“hydrophobic tunnel” found in these cis-prenyl transferase structures is thus essentially blocked 
or occluded in Mcl22, resulting in GPP binding to a new hydrophobic “surface” pocket, 
illustrated by the gray shaded regions shown in Figure 6.4D. The corresponding ligand binding 
pockets in UPPS, Rv1086c and Rv3378c are shown in Figures 6.4A–C. This substrate binding 
site in a cis-prenyl transferase is unprecedented. That is, all other cis-prenyl transferases (with 
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lengthy S1 substrates) bind with the S1 substrate in a vertical orientation, but in Mcl22, GPP 
binds in an essentially horizontal fashion, the more normal orientation being blocked by the 
pincer movement of helices 𝛼2 and 𝛼3. 
6.5 Conclusions & Summary 
6.5.1 Structure-Activity Relationship 
We then produced a series of Mcl22 mutants in which we mutated Mcl22 residues to 
those found in LPPS or UPPS, as shown in Figure 6.5, and measured their activity. As can be 
seen in Figure 6.6A, there are moderate effects on activity with the Y26F and S54A mutations 
(ca. 30–70% decrease in the rate of PPi release), but the effects of the T51W and N57A 
mutations are much larger (ca. 90–95% decrease in activity, Figure 6.6A). Y26 is in close 
proximity to the S1 diphosphate and can facilitate its release after ionization, and S54 and N57 
are involved in H+ abstraction from the carbocation formed after ionization/condensation, as 
discussed below. Both of these residues are found to be important in UPPS catalysis.[4] We also 
found that T51 and N57 had very large effects on activity when using LC-MS to assay product 
formation (at two hours), Figures 6.6B, 6.7. Both the T51W and N57A mutants had the same CD 
spectra as WT protein, Figure 6.8, and the lack of activity of T51W can be attributed to W51 
clashing with DMAPP C3–C5 (Figures 6.9, 6.10). 
6.5.2 Unified Structure-Based Mechanism of Action 
When all of these structural and functional results are taken into account, they lead to 
new, detailed mechanisms not only for Mcl22 but also for LPPS and UPPS. More specifically, 
we propose that since there are no other bases closeby, most -fold proteins use a phosphate-
mediated proton abstraction relay. This is illustrated in Figure 6.11 in which we show the 
substrate-bound structures and distances, condensation reactions, and proton abstraction by a 
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diphosphate oxygen with proton removal through Asn-Ser pairs, for each system. Attempts to 
make the Ser-Asn double mutant in LPPS were not successful, resulting in inclusion body 
formation, but the mechanism is included for the purpose of discussion.  
In Mcl22, the DMAPP double bond attacks C1 in GPP (at d ca. 3.6 Å, Figure 6.11A) 
forming a carbocation. The H2 proton is then removed by a P1 phosphate oxygen (C1–PO1 d ca. 
3.5 Å), the proton then being removed from the active site by a proton shuttle involving N57 and 
S54. The GPP-C1, DMAPP-C2/3, P–O1, N57–O4 and S54–O3 are all perfectly aligned to effect 
these reactions with (sequential) heavy atom distances (Figure 6.11A) of 3.5 Å. What is also of 
great interest is that when the structure of Mcl22 is compared with that of LPPS, it is clear that 
the same proton relay can occur with LPPS, but there the product is 6 (Scheme 6.2) since it is a 
DMAPP methyl proton that is initially abstracted by P–O1, then expelled by the corresponding 
LPPS N124-S121 proton relay (Figure 6.11B). That is, Mcl22 and LPPS generate different 
products (6, 7 in Scheme 6.2) because the PO1–CH distances dictate what products form.  
In UPPS, it is the homoallylic IPP that attacks FPP, and in order to produce the cis-prenyl 
diphosphate, a proton has to be removed from the “IPP” C2. When we examine the X-ray 
structures of UPPS (PDB ID codes 1X08, 1X09) it is clear that essentially the same 
attack/abstraction/relay is involved, Figure 6.11C, with the key role of the Asn-Ser relay 
indicated by our earlier mutagenesis results.[4] So, the Mcl22 structure leads to important 
revisions of previous mechanisms of action of both LPPS (Asn-Ser not proposed) as well as 
UPPS (phosphate as the base not proposed). The role of metal-bound diphosphates acting as 
bases coupled to proton relays in head-to-middle as well as (head-to-tail) cis-prenyl transferases 
thus seems rather general. 
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Another function/structure paper on a head-to-middle prenyl transferase, cyclolavandulyl 
diphosphate synthase, CLDS, was recently reported.[12] The structure is very similar to what we 
find with Mcl22, although the mechanisms of action are different since Mcl22 does not carry out 
the cyclization reaction seen in CLDS. 
The unusual ligand binding mode found in the Streptomyces Mcl22 protein, involved in 
antibiotic biosynthesis, raises another interesting question: are there unusual cis-prenyl 
transferases in other bacteria? Surprisingly, we find that there are bifunctional prenyl transferases, 
expected to form “𝛼” hybrids (Figure 6.12), present in many Streptomyces spp., in which both 
UPPS-like cis-(or ) as well as FPPS- like trans-(or 𝛼) domains are present in a single chain, 
offering intriguing possibilities for finding new isoprenoids.  
In summary, we report the first structure of the “head-to-middle” enzyme 
isosesquilavandulyl diphosphate synthase, involved in the formation of the merochlorin class of 
antibiotics. The structure is remarkable since it represents the first example of a cis-prenyl 
transferase in which the canonical “hydrophobic tunnel” is occluded by a pincer movement of 
two helices, resulting in a new S1 binding pocket not seen in other cis-prenyl transferases. This 
structure then leads to new general mechanisms of action of other “head-to-middle” and cis-
prenyl transferases in which phosphate groups initiate regiospecific proton abstraction, protons 




6.6 Schemes, Tables and Figures 





Scheme 6.2 Structures of the discussed compounds. OPP = diphosphate. 1 = DMAPP, 2 = IPP, 3 






Table 6.1 Data collection and refinement statistics for Mcl22 crystals. 
 Native DMAPP GPP GSPP+DMAPP 
Data collectiona     
Space group P212121 P212121 P212121 P21 
Unit-cell a (Å) 68.12 67.92 65.34 120.96 
b (Å) 121.19 120.65 121.15 68.77 
c (Å) 126.53 126.33 121.25 129.46 
β (°)    90.08 
Resolution (Å) 25–2.0 (2.07–) 25–1.91 (1.98–) 25–2.3 (2.38–) 25–2.14 (2.21–) 
Unique 
reflections 
71134 (6984) 79758 (7741) 42982 (4245) 115165 (11565) 
Reduncancy 4.2 (3.9) 3.2 (3.3) 3.5 (3.5) 3.2 (3.0) 
Completeness (%) 99.2 (98.8) 98.5 (97.1) 99.3 (99.4) 98.1 (99.1) 
Average I/σ(I) 22.8 (2.9) 27.8 (2.7) 24.3 (3.2) 15.3 (5.6) 
Rmerge (%) 5.1 (51.8) 4.8 (45.9) 6.1 (40.1) 6.6 (20.7) 
CC1/2 0.996 (0.947) 0.998 (0.958) 0.997 (0.961) 0.985 (0.929) 
Refinementb     
Resolution (Å) 25–2.0 (2.05–) 25–1.91 (1.96–) 25–2.3 (2.36–) 25–2.14 (2.19–) 
No. of reflections 71082 (4756) 79708 (5413) 42934 (2754) 115108 (7377) 
No. of prot. 
chains 
4 4 4 8 
Rwork (%) 16.88 (23.79) 16.88 (25.44) 18.54 (26.34) 23.25 (26.89) 
Rfree (%) 19.99 (28.04) 19.21 (30.91) 21.47 (36.09) 25.33 (31.00) 
Bond len. rmsd 
(Å) 
0.0063 0.0042 0.0029 0.0033 
Bond ang. rmsd 
(°) 
0.825 0.754 0.611 0.633 
Dihedral angles     
Favored (%) 98.46 98.34 98.34 98.51 
Outliers (%) 0.36 0.24 0.00 0.00 
Aver. B 
(Å2)/atoms 
    
Protein 38.2 /6842 36.2 / 6903 45.4 / 6808 32.5 / 13614 
Ligand 52.8 / 30 57.7 / 153 69.5 / 77 40.2 / 304 
Water 47.5 / 921 46.3 / 904 47.6 / 478 37.6 / 1203 
Clash score 2.15 2.38 3.03 3.52 
MolProbity score 0.99 1.02 1.09 1.33 
PDB code 5XK3 5XK7 5XK8 5XK9 
aNumbers in parentheses are for the outermost resolution shell. bAll positive reflections were 





Table 6.2 Model summary for the Mcl22 crystal structures. 
 
 Native DMAPP GPP GSPP  + DMAPP 
Number of chains 4 4 4 8  
Residues in chain      
A/E A 0 – 216 A 0 – 216 A 0 – 217 A 1 – 214 E 1 – 214 
B/F B 0 – 209 B 0 – 209 B 1 – 209 B 0 – 208 F 0 – 208 
C/G C 1 – 216 C 1 – 217 C -1 – 210 C 0 – 217 G 0 – 216 
D/H D 0 – 209 D 1 – 209 D 1 – 210 D 1 – 209 H 1 – 208 
S1-ligand in chain      
A/E SO4 PPi GPP GSPP GSPP 
B/F SO4 PPi GPP GSPP GSPP 
C/G SO4 PPi GPP GSPP GSPP 
D/H SO4 PPi GPP GSPP GSPP 
S2-ligand in chain      
A/E - PPi - DMAPP DMAPP 
B/F SO4 DMAPP - DMAPP DMAPP 
C/G - DMAPP - DMAPP DMAPP 
D/H SO4 DMAPP - DMAPP DMAPP 
Metal ion in chain      
A/E - Mg - Mg Mg 
B/F - Mg Mg Mg Mg 
C/G - Mg - Mg Mg 
D/H - Mg - Mg Mg 
Other ligands in      
A-chain - MES - - - 
B-chain - MES, SO4 - - - 
C-chain - MES - - - 




Figure 6.1 Structures of isosesquilavandulyl diphosphate synthase (Mcl22). A) Superimposition 
of apo-Mcl22 with UPPS with bound FSPP and IPP (PDB ID codes 1X08, 1X09). B) Mcl22 
with GPP in S1 (PDB ID code 5XK8). C) Mcl22 with PPi in S1 and DMAPP in S2 (PDB ID 
code 5XK7) showing that both diphosphate groups coordinate to Mg2+, as does Asp 9. D) Mcl22 
with GSPP in S1 and DMAPP in S2, together with Mg2+ (PDB ID code 5XK9). Also shown in 
(B–D) are additional conserved residues near/in the active site region. Electron densities are Fo–






Figure 6.2 Stereoview of the structure of isosesquilavandulyl diphosphate synthase (Mcl22) 
illustrating the dimer "butterfly" structure (PDB ID code 5XK3) with SO42- from buffer bound to 






Figure 6.3 Sequence alignments of isosesquilavandulyl diphosphate synthase (Mcl22) or LPPS, 
a tomato zFPPS (cis-FPPS), E. coli UPPS, M. tuberculosis cis-FPPS Rv1086, and M. 
tuberculosis tuberculosinyl adenosine synthase (Rv3378). Highly conserved residues are in 





Figure 6.4 Comparisons between ligand-binding pockets (shown as grey “bubbles”) in E. coli 
UPPS, cis-FPPS (Rv1086, from M. tuberculosis), tuberculosinyl adenosine synthase (Rv3378c, 
from M. tuberculosis) and Mcl22. In all cases the Mcl22 helices are cyan, helices in the other 
proteins are green. Ligands are shown as sticks. A) UPPS+FSPP+IPP (PDB ID codes 1X08, 
1X09) superimposed on Mcl22 (apo, PDB ID code 5XK3). Note the FSPP in UPPS occupies a 
vertical (hydrophobic) pocket. The Mcl22 helices in the center of the protein would clash with 
any large ligand in this region. B) As (A) but Mcl22 is superimposed on (C10) citronellyl 
diphosphate in a cis-FPPS (Rv1086, PDB ID code 2VG0). The Mcl22 helices would occlude a 
potential GPP binding site. C) As (A) but Mcl22 is superimposed on Rv3378 (tuberculosinyl 
adenosine synthase) + tuberculosinyl diphosphate (PDB ID code 3WQN). Again, the large 
substrate requires an expanded pocket. D) Mcl22+GPP+DMASPP (PBD ID code 5XK9). Note 
that the ligands and ligand-binding pocket occupy a “near-surface” cavity domain with the GPP 





Figure 6.5. Structure superimposition of Mcl22/DMAPP+GSPP (green), LPPS (cyan), and 
EcUPPS (magenta) showing positions of some residues that were mutated. The Mcl22 structure 
is shown as a cartoon model, the ligands in the complex are shown as a sphere (Mg2+) or sticks. 











Figure 6.6 Catalytic activity of wild-type Mcl22 and various mutants. A) Determined by using a 
PPi-release assay (t= 0-10 min). B) Determined by using an LC-MS end-product formation assay 
(after 2-hour incubation) under conditions where there was 100% conversion of substrate to 












Figure 6.7 LC‐MS end‐product formation assay. A) Representative extracted ion chromatograms 
([M‐H]- 381.1) of FPP, Mcl22 WT and mutant products. All experiments were repeated at least 









Figure 6.7 Continued. 
 























(integration), × 107 
Activity % 
GPP 9.4  2.57 ± 0.04   
FPP 12.1 4.13 ± 0.15   
GGPP 14.1 4.98 ± 0.08   
Mcl22 WT  11.5 5.34 ± 0.14 100 ± 3 
M11H 11.5 5.15 ± 0.09 96 ± 2 
M11N 11.5 5.29 ± 0.14 99 ± 3 
Y26H 11.5 5.24 ± 0.17 98 ± 3 
Y26F 11.4 5.04 ± 0.003 95 ± 0.06 
M29G 11.5 5.24 ± 0.12 98 ± 2 
T51W  11.5 0.084 ± 0.005 1.6 ± 0.1 
T51Y 11.5 4.91 ± 0.04 92 ± 0.7 
S54A 11.5 3.94 ± 0.20 73 ± 3.7 
N57A 11.5 0.044 ± 0.015 8.3 ± 0.3 




Figure 6.8 Circular dichroism spectra of wild-type Mcl22 and the two inactive mutants, T51W 







Figure 6.9 Stacking interactions with the S2 ligand. In (A), LPPS (lavender) and zFPPS (green) 
structures are superimposed on Mcl22 (cyan). Some relevant side chains for stacking with the S2 
ligand are indicated. In (B), (C) and (D) each model is shown separately with the stacking 
residues labeled. Note that Phe128 in Mcl22 (B) is homologous to Phe258 in LPPS, and Phe259 
in zFPPS, but is different from Phe128 in zFPPS (D), which instead corresponds to Thr51 in 




Figure 6.10 Illustration that T51 and T51Y permit DMAPP binding to Mcl22, but T51W is too 




Figure 6.11 Mechanisms of action of “head-to-middle” and cis-prenyl transferases (-fold 
proteins). A) Mcl22. DMAPP C2/3 attacks cationic center at C1 in GPP; P1 phosphate oxygen 
abstracts H2 from carbocation; H+ removed from active site by N57-S54 relay. B) LPPS. 
Mechanism basically as in (A) but now H4 removed by P1 phosphate and the N124-S121 relay. 
C) UPPS. Same mechanism but now IPP H2 is removed by phosphate and the N74-S71 relay 








Figure 6.12 Phyre2 structure prediction of an  Rosetta protein from Streptomyces 
viridochromogenes DSM 40736 that contains both cis- as well as trans-prenyl transferase 
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Full Name Abbreviation  
Farnesyl pyrophosphate synthase FPPS 
Farnesyl pyrophosphate FPP 
Prenyl transferase or Prenyltransferase PT 
Undecaprenyl pyrophosphate synthase UPPS 
Undecaprenyl pyrophosphate UPP 
Geranylgeranyl pyrophosphate synthase GGPPS 
Octaprenyl pyrophosphate synthase OPPS 
Octaprenyl pyrophosphate OPP 
Heptaprenyl pyrophosphate synthase HepPPS 
Heptaprenyl pyrophosphate HepPP 
Staphylococcus aureus S. aureus 
Geranyl pyrophosphate GPP 
Thin layer chromatography TLC 
Membrane scaffold protein MSP 
Microscale thermophoresis MST 
Lavandulyl pyrophosphate synthase LPPS 
Lavandulyl pyrophosphate LPP 
Isosesquilavandulyl pyrophosphate synthase ILPPS or Mcl22 
Isosesquilavandulyl pyrophosphate ILPP 
 
 
 
 
 
